EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

International Liver Congress™ 2022

 

22-26 June, 2022 London
Close
N. Poster
Poster title
Applicant name
Status
  FL-001 Chemokine receptor (CCR2 and CCR8) peptide antagonist asa promising treatment for non-alcoholic steatohepatitis (NASH) E. Geervliet Received Received
  SAT-001 The DNA damage response is involved in the metabolic dysregulation of MAFLD patients via inefficient fatty acid oxidation Beatriz Gomez Santos Received Received
  THU-001 Heavy alcohol intake along with ALDH2 polymorphism increases the risk of hepatocellular carcinoma and mortality in hepatitis B virus-related cirrhosis Chih-Wen Lin Received Received
  FRI-001 Obeticholic acid exacerbates the liver fibrosis of bile duct ligation model by inducing the liver expression of osteopontin Jie Wang Received Received
  THU-002 Biomarkers for prediction of alcohol-related liver cirrhosis in the Swedish general population Gustav Jakobsson Received Received
  SAT-002 Hepatic miR-144 drives fumarase activity preventing NRF2 activation during obesity Valerio Azzimato Received Received
  FL-002 Role of PDIA4 in Alpha 1-Antitrypsin Deficiency Marion Bouchecareilh Received Received
  FRI-002 A report on the Australian Drug Induced Liver Injury Network: AusDILIN Amanda Nicoll Received Received
  FL-003 EVALUATION OF THE ROLE OF HNF1B DEFICIENCY IN CHOLESTATIC LIVER DISEASE M. Pinon Received Received
  THU-003 A history of bariatric surgery is independently associated with a younger age at onset of severe alcoholic hepatitis Lukas Van Melkebeke Received Received
  FRI-003 Incidence, phenotype and prognostic relevance of COVID-19-related liver injury across different age strata Lukas Hartl Received Received
  SAT-003 TNFR1 inhibition reduces lipogenesis and improves insulin resistance and fibrosis in NAFLD Heike Bantel Received Received
  FL-004 The stellate cell clock in liver fibrosis M. Johanns Received Received
  SAT-004 Obesity alters the partitioning of glycerol metabolism pathways in NAFLD Jack Carruthers Received Received
  FRI-004 Two different types of COVID-19 vaccines and serial liver biochemistries Grace Wong Received Received
  THU-004 Cyclophilin inhibitor CRV431 as a potential therapy for alcohol-related liver disease Elena Palma Received Received
  FL-005 Overcoming resistance to immune checkpoint inhibitors in HCC Ugne Balaseviciute Received Received
  THU-005 UK national service evaluation of transplant assessments for patients with alcohol related liver disease Christopher Oldroyd Received Received
  SAT-005 Human induced pluripotent stem cell-derived mesenchymal stem cells ameliorates mitochondrial oxidative dysfunction in non-alcoholic fatty liver disease Min Kyung Park Received Received
  FRI-005 Role of liver biopsy in management of immune checkpoint inhibitors hepatitis: a single-center retrospective study Lucia Parlati Received Received
  FRI-006 Immune checkpoint inhibitors induced liver injury: an observational study Lucy Meunier Received Received
  SAT-006 Skeletal muscle-derived myokine affects insulin sensitivity and lipogenesis in a human hepatocyte spheroid model Jean-Baptiste Potier Received Received
  FL-006 Natural antibodies are required for cell debrisclearance and liver repair during necrotic liver injury M. Mattos Received Received
  THU-006 Fibroblast growth factor 21 is the main alcohol responsive peptide hormone in humans and individuals with alcohol use disorder exihibit increased plasma concentrations after alcohol intake Amalie Lanng Received Received
  THU-007 Tight junction damage and increased gut permeability in alcohol-related liver disease may be mediated by gut proteases Charlotte Skinner Received Received
  FRI-007 Liver toxicities of immune checkpoints inhibitors for cancer: a multicenter retrospective study Lucia Parlati Received Received
  SAT-007 Patient-derived liver organoids to reveal PNPLA3 I148M role in Non-Alcoholic Fatty Liver Disease Elia Casirati Received Received
  THU-008 Incident acute kidney injury in severe alcohol-related hepatitis is strongly associated with mortality and can be predicted using micro-RNAs and markers of systemic inflammation Luke Tyson Received Received
  FRI-008 Acute severe presentation of autoimmune hepatitis: a 20-year retrospective review of the United States Thomas Enke Received Received
  SAT-008 Transcriptomic analysis confirms that PNPLA3 I148M variant is associated with impaired mitochondrial function and antioxidant response in 3D cultured human hepatic stellate cells and liver tissue of patients with NAFLD Elisabetta Caon Received Received
  FRI-009 Single-cell metabolic profiling of primary human hepatocytes shows heterogenous responses to drug metabolism Eva Sofía Sánchez Quant Received Received
  THU-009 The impact of addiction team integration into the management of patients transplanted for alcohol-related liver disease: results from a multicenter comparative study Jules Daniel Received Received
  SAT-009 HTD1801 (berberbine ursodeoxycholate), a unique single molecule with multiple beneficial effects in metabolic and liver diseases Kjersti Swearingen Received Received
  FRI-010 Management of severe, steroid-resistant and steroid-refractory hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy Morven Cunningham Received Received
  SAT-010 Metabolic, biochemical, histopathological and transcriptomic effects of long-acting FGF21 analogue in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH Malte Hasle Nielsen Received Received
  THU-010 Risk of fractures and subsequent mortality in alcohol-related cirrhosis: a nationwide population-based cohort study Axel Wester Received Received
  THU-011 Use of statins among patients with cirrhosis due to alcohol-related liver disease - a danish nationwide cohort study Anna Marine Slling Ramsing Received Received
  FRI-011 Activation marker CD69 differentiates non-alcoholic steatohepatitis from drug-induced liver injury Alberto Garcia Garcia Received Received
  SAT-011 NAFLD-induced encephalopathy is associated with low-grade brain tissue hypoxia and inflammation, as well as cerebrovascular, glial, metabolic and behavioural alterations Anna Hadjihambi Received Received
  FRI-012 Natural antibodies are required for necrotic cell debris clearance and liver repair during necrotic liver injury Matheus Mattos Received Received
  THU-012 Antibody response to gut microbiome bacteria in human alcoholic liver disease Antonella Putignano Received Received
  SAT-013 Targeted metabolomics reveals alterations in one-carbon metabolism in NAFLD patients Mikkel Werge Received Received
  FRI-013 Human paracetamol hepatotoxicity is mitigated by the gut-liver axis in vitro Martin Vandeputte Received Received
  THU-013 Socio-economic factors and healthcare setting are independently associated with medium and long-term outcomes from alcohol-related hepatitis Joshua Lambert Received Received
  THU-014 Sex-related differences in outcomes in alcohol-related cirrhosis following an episode of hepatic decompensation do not explain subsequent management inequalities Aaminah Mohammed Received Received
  FRI-015 Ten-year single center experience in hepatotoxicity due to mushroom poisoning Ozan Sarikaya Received Received
  SAT-015 Deletion of ATR in hepatocytes improves NAFLD features by increasing mitochondrial function Maeva Saroul Received Received
  THU-015 Influence of comorbidities and lifestyle factors on health-related quality of life in alcohol-related liver disease: a population-based survey Karen Dombestein Elde Received Received
  SAT-016 The AXL inhibitor bemcentinib reduces inflammation and fibrosis by inducing a dynamic change in macrophages and CD8T cells subsets during experimental NASH Sturla M. Groendal Received Received
  THU-016 Patient and system-level factors underline offering and acceptance of alcohol use disorder therapy in veterans with cirrhosis Jasmohan S Bajaj Received Received
  FRI-017 The association between chronic Colchicine use and incident decompensated cirrhosis Michal Carmiel Received Received
  SAT-017 Human Liver Organoids with myeloid lineages model the multi-cellular crosstalk in Non-Alcoholic Steatohepatitis Milad Rezvani Received Received
  THU-017 24-Norursodeoxycholic acid ameliorates experimental alcoholic liver disease in both preventive and therapeutic settings Christoph Grander Received Received
  THU-018 Impact of sex and recurrence in the prognosis of alcoholic hepatitis Jordi Gratacós-Ginès Received Received
  FRI-018 Inhibition of C-C motif chemokine receptor 2 (CCR2) using a novel in silico designed peptide attenuates macrophage migration in vitro and intrahepatic monocyte recruitment in vivo Eline Geervliet Received Received
  SAT-019 Increased liver content of omega-3-derived lipid mediators associates with enhanced mitochondrial oxidative phosphorylation, fatty acid oxidation and metabolic efficiency Cristina López-Vicario Received Received
  FRI-019 Murine intrahepatic regulatory t cells modulate acute liver inflammation by promoting a protective and restorative microenvironment Ada Kurt Received Received
  THU-019 Hepatocyte-derived biomarkers concentrations predict liver-related events within 2 years in patients with Child-Pugh class A alcohol-related cirrhosis LAURE ELKRIEF Received Received
  FRI-020 Place of steroids and prognosis factors for grade =3 immune-checkpoint inhibitors induced hepatitis: a 6-year prospective study Eleonora De Martin Received Received
  THU-020 Dynamic multiomics analysis characterizes circulating molecular determinants associated with poor outcome in patients with severe alcoholic hepatitis Jaswinder Maras Received Received
  SAT-020 Factors associated with increased gut permeability and severity of liver disease in diabetic patients with NAFLD Roberta Forlano Received Received
  FRI-021 The role of macrophage ETS Proto-oncogene 2 in acute-on-chronic liver failure Lulu He Received Received
  SAT-021 Increased burden of inherited IRF3 rare genetic variants in Europeans with severe Non-alcoholic fatty liver diease Alessandro Cherubini Received Received
  THU-021 Alcohol-induced changes of inflammatory markers in hepatic and systemic venous blood in early alcohol-related and non-alcoholic fatty liver disease Evelina Stankevic Received Received
  SAT-022 Sex-dependent hepatoprotective role of IL-22 in NAFLD-related fibrosis Mohamed Noureldin Hassan Ali Abdelanbi Received Received
  FRI-022 Novel strategies required to further improve outcomes in Acute Liver Failure. William Bernal Received Received
  THU-022 New treatment for alcohol-related liver disease: combinations of efficacy and treatment cost required for cost-effectiveness Davit Khlghatyan Received Received
  SAT-023 Identification of novel targets in adipose tissue involved in non-alcoholic fatty liver disease progression Jose M Arbones-Mainar Received Received
  FRI-023 Human liver biopsies from people with hemophilia A who received factor VIII gene transfer with valoctocogene roxaparvovec (AAV5-hFVIII-SQ) show unremarkable histopathology and reveal interindividual variability in transgene production Sylvia Fong Received Received
  THU-023 Active alcohol misuse is linked with lower short-chain fatty acid producing microbiota in a matched study of 450 patients with cirrhosis Jasmohan S Bajaj Received Received
  FRI-024 Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients Miki Scaravaglio Received Received
  THU-024 Infections are common in patients with early alcohol-related liver disease and increases the risk of death Stine Johansen Received Received
  SAT-024 Isoleucine and valine correct hepatic lipid processing, reduce liver steatosis and suppress inflammation in obese mice with manifest NASH Eveline Gart Received Received
  THU-025 Abstinence is associated with better outcome in patients with hepatocellular carcinoma Astrid Marot Received Received
  SAT-025 Butyrate protects against diet-induced NASH and liver fibrosis and suppresses specific non-canonical TGFB signaling pathways in human hepatic stellate cells Eveline Gart Received Received
  FRI-025 Exogenous fibroblast growth factor 7 improved hepatocyte regeneration and ameliorated CCl4-induced acute liver injury in vivo Eline Geervliet Received Received
  SAT-026 Experimental non-alcoholic fatty liver disease causes regional liver functional deficits while total metabolic liver function is preserved Peter Lykke Eriksen Received Received
  THU-026 In severe alcohol-related hepatitis, hepatocyte ballooning correlates with expression of p16 and components of a secretory phenotype that has been associated with cellular senescence Nikhil Vergis Received Received
  FRI-026 Three COVID-19 medications - remdesivir, molnupiravir and ritonavir-boosted nirmatrelvir - and serial liver biochemistries in 22,456 subjects Grace Wong Received Received
  THU-027 Targeting cyclin M4 as a new therapeutical approach to treat alcoholic liver disease Irene Gonzalez Recio Received Received
  SAT-027 Hepatic lipid fingerprint reveals sex-dependent lipid droplet composition in metabolic associated fatty liver disease Elisabet Rodríguez Tomàs Received Received
  FRI-027 TRENDS IN LIVER TRANSPLANTATION FOR ACUTE LIVER FAILURE. A SPANISH MULTICENTER STUDY Isabel Conde Amiel Received Received
  SAT-028 Lipidomics and proteomics reveal mitochondrial dysfunction in liver and visceral adipose tissue from patients with nonalcoholic steatohepatitis Helena Castañé Received Received
  THU-028 Hepatic transcriptional signature of alcohol on genes involved in canonical retinoid metabolism Steven Trasino Received Received
  FRI-028 Hepatobiliary disease after bone marrow transplant Maria Dezan Received Received
  SAT-029 Targeting liver glutaminase 1 modulates hepatic ammonia in experimental Non-Alcoholic Steatohepatitis Maria Mercado-Gómez Received Received
  THU-029 COVID-19 pandemic impact on alcoholic hepatitis healthcare utilisation Leya Nedumannil Received Received
  FRI-029 FOXA2 prevents hyperbilirubinemia through maintaining apical MRP2 expression in acute liver failure Sai Wang Received Received
  FRI-030 Machine learning encoding of liver biopsy images enables prediction of molecular measurements in a NASH F3/F4 fibrosis clinical cohort Michael D. Bereket Received Received
  SAT-030 Clinical relevance of an animal model of nonalcoholic steatohepatitis (NASH) and digital pathology with artificial intelligence (DP-AI) analyses of hepatic fibrosis Deming Xu Received Received
  SAT-031 Small changes in the metabolism of bile acids by the gut microbiota are associated to NASH pathogenesis Justine Gillard Received Received
  THU-031 Untargeted lipidomics unveils a specific plasma signature of severe alcoholic hepatitis Florent Artru Received Received
  FRI-031 Validation of AI-assisted method of liver fat measurement in adults with type 2 diabetes Tim St Pierre Received Received
  SAT-032 Unravelling the landscape of adipose tissue macrophages in human non-alcoholic fatty liver disease Markus Boesch Received Received
  THU-032 Toll-like receptor 2 activation in monocytes of alcohol use disorder patients contributes to systemic inflammation and alcohol-associated liver disease Luca Maccioni Received Received
  FRI-032 Identifying advanced liver disease in asymptomatic patients in primary care: an evaluation of patient outcomes 24 months after implementing a primary care liver pathway and community liver service Tina Reinson Received Received
  THU-033 Improving NIAAA criteria for the diagnosis of alcoholic hepatitis, role of systemic inflammation EMMA Avitabile Received Received
  FRI-033 Predictive survival-time modelling of Non-Alcoholic Steatohepatitis (NASH) fast progressors using real-world evidence Nils Svangrd Received Received
  SAT-033 Atorvastatin attenuates diet-induced non-alcoholic steatohepatitis in ApoE3-Leiden mice by reducing hepatic inflammation José A. Inia Received Received
  SAT-034 Carnitine signature in liver corretales with nonalcoholic fatty liver disease progression Andrea Jiménez Franco Received Received
  THU-034 Alcohol associated hepatitis in Latin America: results from the AH-LATIN study Jorge Arnold Received Received
  FRI-034 Online education significantly improved gastroenterologists knowledge of the diagnostic and monitoring techniques used in liver fibrosis James White Received Received
  SAT-035 Type 2 diabetes and religious fasting: effects on metabolism and liver steatosis Svenja Sydor Received Received
  FRI-035 Health outcomes and risk assessment in chronic liver disease (HERALD): a large Swedish research platform Emilie Toresson Grip Received Received
  THU-035 Prophylaxis of withdrawal syndrome decreases mortality in patients with alcohol-associated hepatitis David Marti-Aguado Received Received
  THU-036 The use of pharmacotherapy in the treatment of alcohol use disorder Kathryn Allen Received Received
  FRI-036 Impact of alcohol use on the diagnostic performance of serum-based indices for fatty liver disease Oscar Danielsson Received Received
  SAT-036 The I48M PNPLA3 variant mitigates Niacin beneficial effects: how the genetic screening in non-alcoholic fatty liver disease (NAFLD) patients gains value erika paolini Received Received
  THU-037 Application of machine learning algorithms to classify steatohepatitis on liver biopsy Resham Ramkissoon Received Received
  SAT-037 The co-presence of PNPLA3, MBOAT7 and TM6SF2 loss-of-functions impairs mitochondrial morphology and number in severe NAFLD patients Miriam Longo Received Received
  FRI-037 Liver stiffness on magnetic resonance elastography and liver-related outcomes in nonalcoholic fatty liver disease: a systematic review and meta-analysis of individual participants Veeral Ajmera Received Received
  SAT-038 The association of spleen volume with sex, age, type 2-diabetes, and non-alcoholic fatty liver disease - initial results from more than 35,000 UK Biobank participants Lars Johansson Received Received
  FRI-038 Utilising features of metabolic syndrome to cost-effectively improve metabolic dysfunction-associated fatty liver disease diagnosis rates Cassandra Baiano Received Received
  FRI-039 Non-invasive assessment of type VII collagen degradation is related to NAFLD activity but not fibrosis stage Mette Juul Nielsen Received Received
  THU-039 Alcoholic foamy degeneration: a unique variant of ALD that shows a characteristic pattern of gene expression with upregulation of lipid metabolism and mitochondrial genes and downregulation of fibrosis genes Jordi Gratacós-Ginès Received Received
  SAT-039 Targeting adipose tissue macrophages ameliorates hepatic injury in a murine model of NAFLD Celia Martínez Sánchez Received Received
  SAT-040 Multiplex immunostaining and transcriptomic profiling identify novel immune cell markers for non-alcoholic steatohepatitis and primary sclerosing cholangitis Adrien Guillot Received Received
  THU-040 Loss of solute carrier family 38 member 4 (SLC38A4) as a driver for the pathogenesis of severe alcoholic hepatitis Nchimunya Nelisa Tebeka Received Received
  FRI-040 Reliability of histologic disease activity measures in non-alcoholic fatty liver disease (NAFLD) and development of an expanded NAFLD activity score Rohit Loomba Received Received
  FRI-041 Evaluating future risk of NAFLD fibrosis in adolescents: prediction and decision curve analysis Kushala Abeysekera Received Received
  THU-041 Refining the natural history of alcohol related liver disease: a competing risk analysis Richard Parker Received Received
  SAT-041 Phospholipid fingerprints reveal sex differences in the adipose tissue phospholipid composition from morbidly obese patients Gerard Baiges Received Received
  FRI-042 Quantification of hepatic steatosis in patients with non-alcoholic fatty liver disease: comparison of sound speed, attenuation coefficient and continuous CAP measurements with MRI-PDFF Rémi COLLIN Received Received
  SAT-042 Ubiquitination of GSDMD regulated by NEDD4 is involved in hepatocyte pyroptosis of nonalcoholic steatohepatitis Rui Jin Received Received
  THU-042 Potential biomarkers for differentiating alcoholic hepatitis from decompensated cirrhosis by serum metabolomic analysis Adelina Horhat Received Received
  FRI-043 Community NAFLD screening programme in patients with type 2 diabetes mellitus indicates high burden of undiagnosed liver disease Emma McCormick Received Received
  SAT-043 Unraveling the transcriptional dynamics of NASH pathogenesis affecting atherosclerosis development Geurt Stokman Received Received
  THU-044 Trends of alcohol-related liver disease hospitalisation during the COVID-19 pandemic Richard Goodheart Received Received
  FRI-044 Non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus in Greenland Rasmus Hvidbjerg Gantzel Received Received
  SAT-044 Repeated weight cycling in obese mice improves hepatic inflammation Geurt Stokman Received Received
  THU-045 Increased hospital admissions for alcohol-associated hepatitis during the COVID-19 pandemic in Alberta, Canada: A retrospective cohort study Alexandra Frolkis Received Received
  FRI-045 A baseline signature of metabolites involving the gut-liver axis predicts MRI-PDFF response to FASN inhibitor TVB-2640: results from the FASCINATE-1 study Rohit Loomba Received Received
  SAT-045 The functional roles of BMP10 in the pathogenesis of nonalcoholic fatty liver disease Wenjun Zhang Received Received
  FRI-046 Enchanced Liver Fibrosis test in predicting severe liver-related outcomes in the general population Kustaa Saarinen Received Received
  SAT-046 Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with severe hepatic impairment Liz Artwick Received Received
  THU-046 The lysosomal enzyme cathepsin D as a new marker for alcoholic liver disease Ronit Shiri-Sverdlov Received Received
  SAT-047 Amino acid glycine suppresses steatohepatitis and tumorigenesis in hepatocyte-specific phosphatase and tensin homolog knockout mice Kazuyoshi Kon Received Received
  THU-047 Ductular bilirubinostasis is a diagnostic biomarker for acute-on-chronic liver failure: results from a well-defined cohort of patients with alcoholic steatohepatitis Annelotte Broekhoven Received Received
  FRI-047 Radiowater perfusion PET of the liver, and its value as a biomarker to discriminate between NAFLD and NASH, and activity and fibrosis grade Olof Eriksson Received Received
  SAT-048 Advanced quantitative phenotypic fibrosis and steatosis scoring is more superior to histology-based conventional staging in NASH animal models Li Chen Received Received
  THU-048 The most recent and in-depth meta-analytic assessment of the global epidemiology of Nonalcoholic fatty liver disease (NAFLD) Carey Escheik Received Received
  FRI-048 The combination of the ELF and FIB-4 scores have high predictive performance for significant fibrosis in patients with NAFLD Carey Escheik Received Received
  SAT-049 Chemical suppression of adipose triglyceride lipase improves nonalcoholic steatohepatitis in a diabetic and hyperlipidemic mouse model Emmanuel Dauda Dixon Received Received
  FRI-049 Association of the biological age and the level of global deoxyribonucleic acid methylation with metabolic parameters in patients with non-alcoholic fatty liver disease Anastasiia Radchenko Received Received
  THU-049 Comorbidities and Malignancy among NAFLD patients compared to general population Naim Ab-Freha Received Received
  SAT-050 Methionine adenosyltransferase 1a antisense oligonucleotides induce the fibroblast growth factor 21-driven recovery from obesity and associated hepatoesteatosis Xabier Buque Received Received
  FRI-050 LEARN algorithm: a novel option for predicting non-alcoholic steatohepatitis Gang Li Received Received
  THU-050 The prevalence of non-alcoholic fatty liver disease in the United Kingdom: a systematic review and meta-analysis Yusef Alenezi Received Received
  FRI-051 Head to head comparison between MEFIB versus MAST for identification of high-risk patients with NAFLD Beom Kyung Kim Received Received
  SAT-051 NLRP3 inflammasome dependent cell death in myeloid cells drives liver inflammation and fibrosis in murine steatohepatitis Benedikt Kaufmann Received Received
  THU-051 Health-related quality of life is impaired in people living with HIV and hepatic steatosis Maurice Michel Received Received
  SAT-052 The PNPLA3 I148M variant increases intrahepatic lipolysis and beta oxidation and decreases de novo lipogenesis and hepatic mitochondrial function in humans Panu Luukkonen Received Received
  FRI-052 MRI assessment (cT1) with LiverMultiScan following VCTE improves the diagnostic yield for high-risk NASH Cayden Beyer Received Received
  THU-052 Moderate alcohol consumption is associated with significant fibrosis progression in non-alcoholic fatty liver disease - a cohort study with over 17 years of follow-up Julia Blomdahl Received Received
  SAT-053 Two diseases, one model - assessing the suitability of FOZ mice to examine CVD in NAFLD Sebastian Bott Received Received
  THU-053 Prevalence trends of non-alcoholic fatty liver disease among young men in Korea: korean military population-based cross-sectional study Jaejun Lee Received Received
  FRI-053 The PNPLA3 (rs738409) G/G-genotype is associated with presence of NASH and increased long-term risk of cirrhosis in NAFLD Magnus Holmer Received Received
  FRI-054 Hepatic expression of secreted calcium-binding protein 2 by hepatic stellate cells is associated with human non-alcoholic fatty liver disease progression Frederik Larsen Received Received
  THU-054 Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: a systematic review and meta-analysis James Thomas Received Received
  SAT-055 The ubiquitin-like modifier FAT10 is upregulated during NASH and impairs PPAR-alpha activity Ludivine Clavreul Received Received
  THU-055 Association of non-alcoholic fatty liver disease and fibrosis with incident dementia and cognitive function: the Rotterdam Study Laurens Van Kleef Received Received
  FRI-055 Clinicians perspectives on barriers and facilitators for the adoption of non-invasive liver tests: a mixed-method study Yasaman Vali Received Received
  THU-056 High meat consumption is prospectively associated with non alcoholic fatty liver disease and liver fibrosis markers Dana Ivancovsky Wajcman Received Received
  SAT-056 TNF-alpha knockout mice are protected from diet-induced NAFLD in a model of non-obese NAFLD Katharina Burger Received Received
  FRI-056 Ectopic fat deposition in the liver and pancreas and the presence of excess visceral adipose tissue significantly increase hospitalisation risk following COVID-19 Tom Waddell Received Received
  SAT-057 Low dose thyroid hormone improves hepatic mitochondrial fatty acid oxidation and rescues nonalcoholic fatty liver disease in mice Raghu Ramanathan Received Received
  THU-057 Relevance of diabetes medication on recruitment criteria for clinical studies in patients with nonalcoholic fatty disease and type 2 diabetes mellitus Johannes Wiegand Received Received
  FRI-057 Genomic and metabolomic profiles and their correlations with preclinical signs of endothelial dysfunction measured by peripheral arterial tonometry in non-alcoholic fatty liver disease Mario Masarone Received Received
  THU-058 Comorbidity severity scores and cardiovascular comorbidities in patients with non-alcoholic steatohepatitis (NASH), with and without cirrhosis, in a real-world setting Jeffrey Lazarus Received Received
  FRI-058 Determinants of liver stiffness measurements in patients with NAFLD - an individual patient data meta-analysis Ferenc Mozes Received Received
  SAT-058 Three-dimensional imaging of cleared human liver tissues reveals extensive fibrosis heterogeneity in non-alcoholic fatty liver disease Buket Yigit Received Received
  THU-059 NAFLD association with renal impairment in type 2 diabetes patients Jesús Rivera-Esteban Received Received
  FRI-059 Knowledge of liver fibrosis stage among adults with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis improves adherence to life style changes Jeffrey Lazarus Received Received
  SAT-060 Hepatic insulin resistance is the basis of bile acid dysmetabolism in non-alcoholic fatty liver disease Sami Qadri Received Received
  FRI-060 The MRI and AST (MAST) score is correlated with noninvasive and histologic markers of fibrosis in patients with advanced fibrosis due to NASH Mazen Noureddin Received Received
  THU-060 The impact of liver fibrosis on the immune response to SARS-CoV-2 vaccination in metabolic associated fatty liver disease patients Marta Freitas Received Received
  THU-061 Non-alcoholic steatohepatitis is also becoming a major liver transplant indication in Spain, a historically low risk area Laura Martínez-Arenas Received Received
  SAT-061 Non-alcoholic fatty liver disease features a reduced reverse polyunsaturated fatty acid transport (free fatty acids/high-density lipoprotein) from the periphery to the liver Gabriele Mocciaro Received Received
  FRI-061 Independent determinants of CAP values in healthy individuals with dysmetabolism Cristiana Bianco Received Received
  THU-062 Total healthcare cost and characteristics associated with higher change in cost in patients with non-alcoholic steatohepatitis Zobair Younossi Received Received
  FRI-062 Performance of liver-related clinical scores in the SAPHIR study Lorenz Balcar Received Received
  FRI-063 Correlations of 2D-Shear wave and transient elastography liver stiffness measurements in patients with non-alcoholic fatty liver disease Dimitrios Karagiannakis Received Received
  SAT-063 FXR binding and transcription in the liver is signficantly altered in obese patients with NAFLD Martin Wagner Received Received
  THU-063 Nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) is associated with worse outcomes in patients hospitalised for COVID-19: a real-world analysis of a large population from the premier healthcare database Frank Tacke Received Received
  FRI-064 Performance of the Enhanced Liver Fibrosis (ELF) test in real world practice versus clinical trials of non-alcoholic steatohepatitis Carey Escheik Received Received
  SAT-064 Non-alcoholic fatty liver disease (NAFLD) progression to non-alcoholic steatohepatitis (NASH) and NASH-related hepatocellular carcinoma (HCC ) evolves following a differential activation of Endoplasmic Reticulum Stress responses Alexander Nicholas Finnemore Capon Diaz Received Received
  THU-064 Estimating the prevalence of advanced fibrosis due to nonalcoholic fatty liver disease in the United States population Naim Alkhouri Received Received
  FRI-065 Machine learning using simple non-invasive tests of fibrosis and B-mode ultrasound for the prediction of adverse liver-related outcomes in NAFLD Heather Kosick Received Received
  SAT-065 MPEP, an mGlu5 receptor allosteric modulator, reduces hepatic steatosis in obese high-fat-diet mice Laura Giuseppina Di Pasqua Received Received
  THU-065 Non-alcholic fatty liver disease associated liver fibrosis is linked with the severity of coronnary artery disease mediated by systemic inflammation Xianbin Cai Received Received
  SAT-066 Pro-inflammatory liver-homing T cells in peripheral blood, liver and adipose tissue in patients with NASH and changes in post-bariatric surgery samples James Brindley Received Received
  FRI-066 Incorporating a two-tiered liver fibrosis assessment into annual diabetes review in primary care - 3 year follow up study Dina Mansour Received Received
  THU-066 Prevalence of portal vein thrombosis in non-alcoholic fatty liver disease related cirrhossis: a meta-analysis of observational studies Roberta Stupia Received Received
  THU-067 Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-nonalcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy Federico Ravaioli Received Received
  SAT-067 Therapeutic inhibition of complement component 5 does not reduce NASH progression but does attenuate atherosclerosis development in Ldlr-/-.Leiden mice Florine Seidel Received Received
  FRI-067 New scoring system using MRI with AST for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis Kento Imajo Received Received
  FRI-068 Impact of artificial intelligence assistive tool on the histopathologic review of fibrosis in non-alcoholic steatohepatitis patients Elaine Chng Received Received
  THU-068 Postprandial dysfunction in metabolic associated fatty liver disease (MAFLD) Josephine Grandt Received Received
  SAT-068 The overexpression of TM6SF2 and/or MBOAT7 wild-type genes re-establishes the mitochondrial dynamics in an in vitro NAFLD model. erika paolini Received Received
  SAT-069 CD1d knockdown promotes NAFL lipid synthesis by activating the IL6-JAK1-STAT3 signal pathway and reduces inflammatory factors in NASH by decreasing macrophage polarisation towards M1 and increasingn polarisation towards M2 Dandan Shan Received Received
  THU-069 Lean non-alcoholic fatty liver disease patients from the global NASH registry Carey Escheik Received Received
  FRI-069 PRO-C3 based sequential algorithm can screen high-risk NASH and severe fibrosis in asian NAFLD population Liang-Jie Tang Received Received
  THU-070 Automated FIB-4 calculator and targeted provider education improved referral of at-risk fibrotic NAFLD patients Cindy Piao Received Received
  FRI-070 Real-world use of the FIB-4 calculator in primary care workflows to screen for advanced non-alcoholic fatty liver disease in a large US health system George Therapondos Received Received
  SAT-070 The role of immune semaphorins in NAFLD - a pilot study Ivana Knezevic Stromar Received Received
  FRI-071 In silico identification and validation of plasma Ficolin-2 (FCN-2) as non-invasive biomarker of fibrosis in Non-alcoholic Fatty Liver Disease (NAFLD) Noel Salvoza Received Received
  SAT-071 Machine learning-enabled continuous scoring of histologic features facilitates prediction of clinical disease progression in patients with non-alcoholic steatohepatitis Janani Iyer Received Received
  THU-071 Long term outcomes of non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD) Carey Escheik Received Received
  THU-072 MARC1 and HSD17B13 variants have protective effects on liver injury in the obese: results from a prospective cohort of patients undergoing bariatric surgery Marcin Krawczyk Received Received
  FRI-072 A lower cut-off of liver stiffness measurement (8/13) kPa performs better than Baveno 6 criteria for advanced chronic liver disease in patients with non-alcoholic fatty liver disease Sagnik Biswas Received Received
  SAT-073 Validation of the ADAPT score for the diagnosis of clinically significant fibrosis in patients with nonalcoholic fatty liver disease (NAFLD) Emily Wigginton Received Received
  THU-073 The impact of fatigue on mortality of patients with non-alcoholic fatty liver disease (NAFLD): data from national health and nutrition examination survey (NHANES) 2005-2018 Carey Escheik Received Received
  FRI-073 High prevalence of multi-organ steatosis and fibroinflammation, identified by multi-parametric magnetic resonance imaging, in people with type 2 diabetes Nicole Eichert Received Received
  SAT-074 Obeticholic acid reduces hepatic matrix metalloproteinase activity in a diet-induced ob/ob mouse model of NASH Marta Cagna Received Received
  THU-074 Metabolic dysfunction-associated fatty liver disease increases cardiovascular risk regardless of classical risk factors María Del Barrio Azaceta Received Received
  FRI-074 Plasma TREM2, a novel non-invasive biomarker for diagnosis of NASH in NAFLD patients with elevated liver stiffness Charlotte Wernberg Received Received
  SAT-075 Evaluation of semisynthetic high-fat diets in development of a 4-week mouse NASH model Ozren Majstorovic Received Received
  FRI-075 Unbiased clustering of exhaled breath profiles in metabolic dysfunction-associated fatty liver disease identifies a patient phenotype at higher risk of disease progression Rohit Sinha Received Received
  THU-075 Changes in hepatic fat fraction as assessed by MRI-PDFF are correlated with changes in markers of hepatic inflammation, disease activity and fibrosis in biopsy-proven non-cirrhotic NASH with fibrosis Samuel Daniels Received Received
  THU-076 The metabolic dysfunction-associated fatty liver disease definition, regardless of its clinical subclassification, identifies patients at high risk for liver disease progression María Del Barrio Azaceta Received Received
  FRI-076 The pericellular basement of the hepatocytes is highly affected by bariatric surgery in obese patients with non-alcoholic fatty liver disease Ida Lnsmann Received Received
  SAT-076 Tyrosinase mutations, a novel predisposing genetic factor for enhanced nonalcoholic steatohepatitis susceptibility Kaushalya Kulathunga Received Received
  FRI-077 A re-appraisal of the diagnostic performance of ultrasonography for fatty liver disease Chul-min Lee Received Received
  THU-077 Assessment of the prevalence of nonalcoholic fatty liver disease, its severity, and comorbidities in lean americans: national health and nutrition examination surveys (NHANES) with transient elastography assessment from 2017 to 2018 Emily Truong Received Received
  SAT-078 Recapitulating insulin resistance in a 3D human liver model for efficacy testing of drug candidates Radina Kostadinova Received Received
  THU-078 Coagulation imbalance is associated with hepatic fibrosis and vascular complications in patients with type2 diabetes and NAFLD Rosa Lombardi Received Received
  FRI-078 Cost utility analysis for screening for fibrotic NASH in the type 2 population from European countries Mazen Noureddin Received Received
  FRI-079 Free Light Chains as a potential biomarker of inflammation and fibrosis in non-alcoholic steatohepatitis Antonio Liguori Received Received
  SAT-079 Novel endosomal trafficking adaptor for the regulation of NAFLD to NASH progression Karsten Motzler Received Received
  THU-079 Presence of two or more metabolic risks regardless of fatty liver is a risk factor for significant hepatic fibrosis HUIYUL PARK Received Received
  FRI-080 12-week very low calorie diet in NAFLD induces rapid improvements in biomarkers of necro-apoptosis and fibrogenesis of a magnitude comparable to those seen in phase 2 drug trials Jadine Scragg Received Received
  THU-080 Pregnancy as a unique opportunity to identify NAFLD in women: a prospective assessment Tatyana Kushner Received Received
  SAT-080 Enzymatic activity dysfunction of the mitochondrial respiratory chain, in the full spectrum of the METABOLIC ASSOCIATED FATTY LIVER DISEASE Alberto García Picazo Received Received
  SAT-081 Lipid-induced phenotypic differences in human non-alcoholic fatty liver disease models determined by matrix-assisted laser desorption/ionization mass spectrometry Ruth Walker Received Received
  FRI-081 Signature of circulating hepatic proteins detects fibrosing-steatohepatitis in progressive non-alcoholic fatty liver disease Olivier Govaere Received Received
  SAT-082 Regulation of NEAT1 in NAFLD by RNA-binding proteins Lisa Ahne Received Received
  THU-082 Genetic risk of fatty liver disease and mortality in the general population Helene Gellert-Kristensen Received Received
  FRI-082 Peripheral blood mononuclear cells mitochondrial copy number and adenosine triphosphate inhibition test in non-alcoholic fatty liver disease Eileen L. Yoon Received Received
  SAT-083 Anti-inflammatory effect of simvastatin-ezetimibe combination therapy via inhibition of macrophage in NASH related mouse model Seul Ki Han Received Received
  FRI-083 Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era Dae Won JUN Received Received
  SAT-084 The different modulation of KLB expression impacts on liver damage in NAFLD patients and in an in vitro model: a novel druggable target? Marica Meroni Received Received
  FRI-084 Assessing the applicability of non-invasive diagnostic tests (NITs) in non-alcoholic fatty liver disease: an international qualitative study Maja Thiele Received Received
  THU-084 The association between nonalcoholic fatty liver disease and insulin resistance within normal glucose level population chun-yi Wang Received Received
  SAT-085 Utilization of Gluconeogenic Glucose-6-Phosphate via Pentose Phosphate Pathway is increased in mice fed a high fat/high sugar diet compared to a high sugar diet alone Getachew Debas Belew Received Received
  FRI-085 Evaluation of the performance of a novel digital pathology method for the continuous quantification of steatosis, ballooning and inflammation in liver biopsies and its correlation with NASH-CRN scores in patients with NASH Louis Petitjean Received Received
  THU-085 Chronic pruritus represents a major burden in non-cholestatic hepatobiliary disorders Andreas Kremer Received Received
  THU-086 Mortality prediction in non-alcoholic fatty liver disease using SteatoSITE: an integrated gene-to-patient data commons for high-definition non-alcoholic fatty liver disease research Maria Jimenez Ramos Received Received
  FRI-086 Can combination of M2BPGi and APRI help endocrinologists refer patients with advanced hepatic fibrosis to hepatologists? Mimi Kim Received Received
  SAT-086 A novel microwell platform to analyse single-cell secretion dynamics and cell communication in NAFLD progression Richell Booijink Received Received
  FRI-087 The relationship between foetal head circumference growth trajectories and nonalcoholic fatty liver disease in adolescents Jeffrey Lee Received Received
  THU-087 Different effects of low muscle mass on the risk of non-alcoholic fatty liver disease and liver cirrhosis in a prospective cohort Hun Jee Choe Received Received
  SAT-087 Dysregulation of the urea cycle enzymes determines a more severe NAFLD phenotype in a DIAMOND preclinical model Rocío Gallego-Durán Received Received
  SAT-088 Quantitative multimodal anisotropy imaging enables automated fibrosis assessment of H&E-stained tissue Justin Lee Received Received
  FRI-088 Liver stiffness assessed by transient elastography predicts clinical events in patients with T2DM and NAFLD Jesús Rivera-Esteban Received Received
  THU-088 Age and the relative importance of liver-related deaths in nonalcoholic fatty liver disease Huapeng Lin Received Received
  FRI-089 Repeated noninvasive liver biopsy surrogate LIVERFASt correlates with BMI and liver enzyme improvements Mona Munteanu Received Received
  SAT-089 Zonated quantification of immunohistochemistry in steatotic livers Cédric Peleman Received Received
  THU-089 Hepatic fat as a novel marker for high-risk coronary atherosclerosis in Familial Hypercholesterolaemia: a CT-based study Gavin Huangfu Received Received
  FRI-090 Increased liver stiffness on vibration controlled transient elastography (Fibroscan) as a predictor of all-cause mortality in people with fatty liver disease Michael Braude Received Received
  SAT-090 CD161 expressing CD4 CD25hi T cells accumulate in the liver of obese patients with NASH Rafael Kaeser Received Received
  THU-090 Nonalcoholic fatty liver disease impcat on cardiovascular disease death: a population-based study Chaonan Jin Received Received
  THU-091 Sarcopenia is associated with the severity of metabolic associated fatty liver disease in elderly residents xiaohui liu Received Received
  FRI-091 Magnetic resonance imaging-based biomarker accurately identifies patients with nonalcoholic steatohepatitis and significant liver fibrosis: a multicentre, international, validation study David Marti-Aguado Received Received
  SAT-091 GL0034, A novel long-acting glucagon-like peptide 1 receptor agonist exhibits significant efficacy in aged db/db mouse model of non-alcoholic fatty liver disease (NAFLD) Rajamannar Thennati Received Received
  THU-092 NAFLD patients scheduled for bariatric surgery present with a milder disease phenotype as compared to not morbidly obese NAFLD patients: analysis of a large real-world cohort Monika Rau Received Received
  SAT-092 Development of an ex vivo model for non-alcoholic fatty liver disease using precision-cut liver slices Mei Li Received Received
  FRI-092 Diagnostic accuracy of MRE for staging hepatic fibrosis in patients with NAFLD Manuel Romero Gomez Received Received
  SAT-093 The neolignan honokiol can improve intestinal barrier dysfunction in fructose-induced liver damage in mice Anja Baumann Received Received
  THU-093 Effects of SARS-CoV2 pandemic in a cohort of Italian NAFLD patients Bernardo Stefanini Received Received
  FRI-093 Aldafermin quantitatively improves inflammation in a 24-week clinical trial in patients with nonalcoholic steatohepatitis Tian Lan Received Received
  SAT-094 Retrospective AI-based measurement of NASH histology (AIM-NASH) analysis of biopsies from Phase 2 study of Resmetirom confirms significant treatment-induced changes in histologic features of non-alcoholic steatohepatitis Janani Iyer Received Received
  THU-094 A higher Fibrosis-4 (FIB-4) score is associated with higher healthcare costs and hospitalizations in patients with Nonalcoholic Steatohepatitis (NASH) Elliot Tapper Received Received
  FRI-094 Clinical and economic evaluation of community-based preventative screening strategies for non-alcoholic fatty liver disease in people with Type-2 diabetes melllitus Roberta Forlano Received Received
  SAT-095 Insights to molecular mechanism of Essentiale: In vitro studies in hepatic cell lines HepaRG and steatotic HepaRG Gert Fricker Received Received
  THU-095 Comparison of hepatic and cardiovascular damage between HIV patients with steatosis and NAFLD: role of metabolic alterations and low visceral adiposity Felice Cinque Received Received
  FRI-095 Confounding factors in diagnostic performance of magnetic resonance elastography for staging liver fibrosis in patients with non-alcoholic fatty liver disease: an individual patient data meta-analysis Manuel Romero Gomez Received Received
  THU-096 Impact of intermittent fasting on anthropometric and clinical outcomes in non-alcoholic fatty liver disease: systematic review and meta-analysis Marcia Lange Received Received
  SAT-096 Exposure to the SARS-CoV-2 spike protein in an in vitro model of steatosis enhances hepatocyte oxidative stress: implications for COVID-19 and accelerated disease progression Angus Jacobs Received Received
  FRI-096 Is it possible to identify nonalcoholic steatohepatitis and the associated degree of fibrosis by noninvasive methods in patients with MAFLD? Marta Casado Received Received
  THU-097 The Burden of Liver Fibrosis in the Obese Population Gres Karim Received Received
  FRI-097 The Potential Role of Fatigue in Identifying Patients with NASH and Advanced Fibrosis who Experience Disease Progression Carey Escheik Received Received
  FRI-098 Novel digital pathology quantitative image analysis and AI method detects the treatment effects of NASH drug candidates with a performance that benchmarks imaging-based measurements Mathieu Petitjean Received Received
  THU-098 Impact of screening and treatment of obstructive sleep apnea in non-alcoholic fatty liver disease Kelsey Collins Received Received
  FRI-099 Translational fibrosis phenotypes between the 3D human NASH Spheroidal Model and clinical NASH samples Louis Petitjean Received Received
  THU-099 Undiagnosed NAFLD in the Obese Population: In Sight, Out of Mind Gres Karim Received Received
  FRI-100 Shear Wave Elastography, Transient Elastography and Enhanced Liver Fibrosis Test Use in the Assessment of Non-Alcoholic Fatty Liver Disease (NAFLD) in Real- World Practices Carey Escheik Received Received
  THU-100 Prevalence of non-alcoholic steatohepatitis in patients undergoing laparoscopic cholecystectomy for gallstone with non-alcoholic fatty liver disease Utpal Anand Received Received
  SAT-101 Efficacy and Safety of Leronlimab in Patients with Nonalcoholic Steatohepatitis: Topline Results of NASH01 Clinical Trial Scott Hansen Received Received
  FRI-101 Diagnostic performance of AGILE 3 score for identification of advanced fibrosis and prediction of liver-related events in patients with non-alcoholic fatty liver disease Ciro Celsa Received Received
  THU-101 Lack of awareness of a NAFLD pandemic in a high risk group. Is it time to act in primary care? Maria Fernanda Guerra Veloz Received Received
  THU-102 Nonalcoholic fatty liver disease and type 2 diabetes: low referral rate of patients at increased risk of progressive liver disease Lucy Gracen Received Received
  SAT-102 Reduced triglycerides and LDL cholesterol from once-weekly administration of the well-tolerated novel FGF21 analogue 0499 Kirsten Dahl Received Received
  FRI-102 Diagnostic accuracy of non-invasive tests for cirrhotic NASH - An individual participant data meta-analysis Ferenc Mozes Received Received
  SAT-103 MULTIMODALITY ASSESSMENT OF HEPATIC FIBROSIS:RANKED PAIRED READING AND ARTIFICIAL INTELLIGENCE IDENTIFIES FIBROSIS IMPROVEMENT WITH ARAMCHOL MISSED BY CONVENTIONAL STAGING Shani Ganon Received Received
  FRI-103 Longitudinal ALT trajectories are generally stable among patients with non-alcoholic fatty liver disease (NAFLD): An investigation using artificial recurrent neural networks Michael Fried Received Received
  THU-103 Hypertension and diabetes mellitus are associated with high FIB-4 index in a health checkup examination cohort without known liver disease Shunsuke Sato Received Received
  FRI-104 An adult-based genetic risk score for hepatic fat associates with liver and lipid traits in Danish children and adolescents Yun Huang Received Received
  THU-104 Statins, but not aspirin, reduce the risk of hepatocellular carcinoma and mortality in Danish patients with cirrhosis due to alcohol-related liver disease: a nationwide causal study Frederik Kraglund Received Received
  SAT-104 The effect of glucagon on rates of hepatic mitochondrial oxidation and pyruvate carboxylase flux in man assessed by positional isotopomer tracer analysis (PINTA) Kitt Petersen Received Received
  FRI-105 Identification of new potential biomarkers to follow steatohepatitis in patients with Non-Alcoholic/Metabolic-associated Fatty Liver Disease Douglas Maya Received Received
  SAT-105 Identification of biomarkers of histological response in patients with non-cirrhotic NASH treated with Lanifibranor jerome boursier Received Received
  SAT-106 TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in nonalcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study Susan Huang Received Received
  FRI-106 NASH patients itinerary: Comparison of strategies for screening, referring and management Manuel Romero Gomez Received Received
  SAT-107 Favorable lipid and pruritus profile of liver-distributed farnesoid X receptor agonist TERN-101 at clinically efficacious doses in nonalcoholic steatohepatitis phase 2a LIFT study Susan Huang Received Received
  FRI-107 Peformance of FIBROMETER-derived biomarker panels for assessment of fibrosis stage in NAFLD: NIMBLE stage 1 and the NASH CRN Collaborative Study Daniel Huang Received Received
  FRI-108 Diagnostic accuracy of non-invasive tests for fibrotic NASH - An individual participant data meta-analysis Ferenc Mozes Received Received
  SAT-108 Liver-distributed farnesoid X receptor agonist TERN-101 demonstrates potent target engagement with a favorable exposure-response profile in nonalcoholic steatohepatitis patients Susan Huang Received Received
  FRI-109 Multiparametric MRI biomarker corrected T1 as a prognostic marker in chronic liver disease Cayden Beyer Received Received
  SAT-109 EDP-297: a novel, highly potent, farnesoid X receptor agonist, results of a phase 1 study in healthy subjects Christine Marotta Received Received
  FRI-110 Results of the Non-invasive Biomarkers of Metabolic Liver Disease (NIMBLE) study 1.1 on the reproducibility and repeatability of shear-wave and transient elastography in non-alcoholic fatty liver disease Anthony Samir Received Received
  SAT-110 Weight loss with semaglutide treatment or time-restricted feeding differentially improves non-alcoholic steatohepatitis in diet-induced obese insulin resistant mice Francois Briand Received Received
  FRI-111 Independent association of physical activity with nonalcoholic fatty liver disease and alanine aminotransferase levels Jun Kyu Lee Received Received
  SAT-111 ECC4703, a full thyroid hormone receptor beta (THRb) agonist, demonstrated excellent ivity and liver targeting properties and improvement of plasma lipid, NAFLD acitivty score and fibrosis in NASH animial model Jianfeng Xu Received Received
  SAT-112 LIVRQNac increases fatty acid oxidization in a primary human hepatocyte model of non-alcoholic steatohepatitis Matthew Russell Received Received
  FRI-112 In a nonalcoholic steatohepatitis (NASH) clinical trial, baseline and screen failure magnetic resonance elastography (MRE) liver stiffness values calculated as weighted means were not different from values calculated as simple means Michael Middleton Received Received
  SAT-113 Assessment of therapeutic effect of liraglutide in newly established cell culture model of nonalcoholic and drug-induced fatty liver disease Tea Omanovic Kolaric Received Received
  FRI-113 Influence of pregnancy on NAFLD-associated lipidomic signatures Tatyana Kushner Received Received
  SAT-114 Efx treatment improved histopathology and noninvasive markers of liver injury and fibrogenesis to a similar extent in NASH patients with high-risk PNPLA3 genotypes, compared to those with lowest genetic risk: a post-hoc analysis of balanced study Erik Tillman Received Received
  FRI-114 Plasma sgp130 is an independent predictor of non-alcoholic fatty liver disease severity AYSIM GUNES Received Received
  FRI-115 FIB-4 outperforms other serum non-invasive fibrosis tests in metabolic associated fatty liver disease Nikoletta Maria Tagkou Received Received
  SAT-115 Oxygen-nutrient mismatch: a novel concept to explain how Obeticholic acid benefits NASH treatment Gerond Lake-Bakaar Received Received
  FRI-116 PRESENCE OF AUTO-ANTIBODIES HAS NO IMPACT ON HISTOLOGICAL PARAMETERS IN NON-ALCOHOLIC FATTY LIVER DISEASE AJEET SINGH BHADORIA Received Received
  SAT-116 Sustained reduction of triglyceride and LDL cholesterol from single administration of the novel long-acting FGF21 analogue 0499 Kirsten Dahl Received Received
  FRI-117 Marked underestimation of liver fat content as measured by magnetic resonance versus histologya systematic review and meta-analysis Sami Qadri Received Received
  SAT-117 Combination of an Acetyl-CoA carboxylase inhibitor and obeticholic acid reduced lipids and bile acids and altered lipid and amino acid metabolism in the liver of humanized mice David Hollenback Received Received
  SAT-118 Identification of a fibrosis endotype in NAFLD patients more prone to interventions aimed at reducing fibrogenesis Mette Juul Fisker Received Received
  FRI-118 DISEASE SEVERITY ASSESSMENT OF METABOLIC DYSFUNCTION-ASSOCIATED FATTY LIVER DISEASE IN TAIWAN Jee-Fu Huang Received Received
  SAT-119 The pan-PPAR agonist lanifibranor improves markers of cardiometabolic health in patients with NASH independent of weight change Michael Cooreman Received Received
  FRI-119 Optical analysis of liver magnetic resonance images (MRI) 3T to detect steatohepatitis features: the program DeMILI 3.0. Isabel Fernández-Lizaranzu Received Received
  SAT-120 Lanifibranor therapy reduces the FibroScan-aspartate aminotransferase (FAST) score associated with histological NASH resolution and improvement of fibrosis and biomarker response Michael Cooreman Received Received
  FRI-120 The Fibrosis-4 cut-off value for significant fibrosis is dependent on the type of non-alcoholic fatty liver disease patients Leen Heyens Received Received
  FRI-121 Developing an algorithm to predict NAFLD in clinical trial volunteers - interim report NCT04873258 Dominic Pimenta Received Received
  SAT-121 Effect of smartphone-assisted lifestyle intervention in patients with metabolic-associated fatty liver disease (MAFLD): a preliminary analysis of a randomized controlled trial Suraphon Assawasuwannakit Received Received
  FRI-122 Correlation of Ultrasound derived Fat Fraction (UDFF) with MRI (PDFF): Possibilities and Analysis of Confounding Factors Reinhard Kubale Received Received
  SAT-122 Efficacy and mechanism of time-restricted fasting in non-alcoholic liver disease Jiang Deng Received Received
  FRI-123 ELF to identify NASH and fibrosis in non-alcohol related fatty liver disease Richard Parker Received Received
  SAT-123 Functionalizing novel cancer related genes in liver disease and liver regeneration Nooshin Nourbakhsh Received Received
  SAT-124 Effect of long-term dietary intervention on liver pathology and markers of hepatocellular senescence in the GAN diet-induced obese mouse model of NASH Kristoffer Voldum-Clausen Received Received
  FRI-124 Performance of the Steatosis-Associated Fibrosis Estimator (SAFE) to predict F2 fibrosis and higher in a cohort of South Korean patients with non-alcoholic fatty liver disease (NAFLD) Vivek Charu Received Received
  SAT-125 Fecal microbiota trasplant using endoscopic-placement hydrogel reduces liver fibrosis with no changes in steatosis in a rat model of steatohepatitis with fibrosis Ramon Bartolí Received Received
  FRI-125 FIB-4 combined with positron emission tomography biomarkers detects fibrotic NASH Souvik Sarkar Received Received
  SAT-126 Reversing diet-induced steatohepatitis and CCl4 induced fibrosis with AN1284 treatment Rinat Abramovitch Received Received
  FRI-126 Mitochondria-derived methylmalonic acid is associated with advanced fibrosis risks in metabolic dysfunction-associated fatty liver disease (MAFLD): results from the NHANES 1999-2004 Qi Huang Received Received
  SAT-127 Spontaneous and drug-induced histological changes in nonalcoholic steatohepatitis: an assessment by meta-analysis of trials Grazia Pennisi Received Received
  SAT-128 Synergistic activity of GLP-1 peptide analog XW003 and the long-lasting GIP receptor agonist XW017 in a diet induced obese mouse model Martijn Fenaux Received Received
  SAT-129 Preclinical pharmacology of low molecular weight GLP-1 receptor agonist XW014 Martijn Fenaux Received Received
  SAT-130 Integrated transcriptomics of CRV431 treatment in a Phase 2a NASH trial confirms anti-fibrotic effect of pan-cyclophilin inhibition and identifies CRV431-specific biomarkers Patrick Mayo Received Received
  SAT-131 Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in nonalcoholic steatohepatitis (NASH) patients with compensated cirrhosis Naim Alkhouri Received Received
  SAT-132 HEC96719, a novel tricyclic farnesoid X receptor agonist for treatment of non-alcoholic steatohepatitis: results of preclinical study and phase I trial Yan Wang Received Received
  SAT-133 Effect of saroglitazar in reducing liver enzymes and liver stiffness in non-alcoholic fatty liver disease: a single arm prospective study Avisek Chakravorty Received Received
  SAT-134 Intrahepatic microcirculation disorders and hyperammoniemia and their correction at nonalcoholic steatohepatitis patients with initial stages of liver fibrosis Tatiana Ermolova Received Received
  SAT-135 Ticagrelor, but not clopidogrel, attenuated hepatic steatosis in a model of non-alcoholic fatty liver disease Hyunwoo Oh Received Received
  SAT-136 Lemon balm extract ALS-L1023, an angiogenesis inhibitor, inhibits liver fibrosis in a non-alcoholic fatty liver disease model Hyo Young Lee Received Received
  SAT-137 Hepatocyte-specific JNK signaling is protective during progression of NASH Julia Piche Received Received
  SAT-138 Semaglutide use in adjunct to multidisciplinary lifestyle interventions improves weight and body composition in NAFLD patients Rochelle Wong Received Received
  SAT-139 Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH) Maya Margalit Received Received
  SAT-140 Identification of new therapeutic targets for hepatic regenerative medicine in Non-Alcoholic Fatty Liver Disease (NAFLD) Shainan Hora Received Received
  SAT-141 The effects of dietary vitamin E intake on NAFLD and sex differences in serum metabolic profile Carolin Schneider Received Received
  SAT-142 Favorable safety profile of TERN-201, a highly ive inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study Susan Huang Received Received
  SAT-143 Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH) Naim Alkhouri Received Received
  SAT-144 Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model Andrea Marco Caddeo Received Received
  SAT-145 Safety and pharmacokinetics (PK) of single and multiple ascending oral doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist for the treatment of non-alcoholic steatohepatitis (NASH) , in healthy volunteers and subjects with hyperlipidemia Benedetta Massetto Received Received
  FRI-146 Hepatic angiocrine HGF attenuates liver fibrogenesis via modulation of PDK1/AKT axis Jianye Wang Received Received
  SAT-146 A MEDITERRANEAN DIET INTERVENTION has BENEFICIAL EFFECTS on BIOMARKERS of CARDIOVASCULAR RISK and HEPATIC FIBROSIS in NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) Laura Haigh Received Received
  FRI-147 Bisphosphonate-loaded nanogels attentuate liver fibrosis by repolarization of M2-type macrophages Leonard Kaps Received Received
  FRI-148 Preclinical evaluation of the calpain inhibitor BLD-3051 as a therapeutic strategy for liver fibrosis Ravi Rajagopalan Received Received
  FRI-149 Experimental fibrosis alters matrix-bound vesicles cargo that do not revert after histologic recovery Toshifumi Sato Received Received
  FRI-150 Hepatocyte cell-specific deletion of cathepsin D does not affect liver inflammation and fibrosis during cholestatic-induced liver fibrosis Maria Fernandez-Fernandez Received Received
  SAT-151 CD44 plays critical role in liver regeneration through enhanced redox balancing Wan Seob Shim Received Received
  FRI-151 The therapeutic potential of alpha v integrins in liver fibrosis Syedia Rahman Received Received
  THU-151 Altered fecal microbiome and metabolome in hepatitis B related chronic liver diseases YUE SHEN Received Received
  SAT-152 Development of ECM mimicking 3D-hydrogel scaffolds for liver tissue engineering Nathan Carpentier Received Received
  FRI-152 Dual inhibition of integrins alpha-v/beta-6 and alpha-v/beta-1 decreases portal pressure and liver fibrosis in rats with biliary cirrhosis Philipp Knigshofer Received Received
  THU-152 The therapeutic effect of Lactobacillus plantarum on metabolic phenotypes in non-alcoholic fatty liver disease mice model Dong Yun Kim Received Received
  SAT-153 Three-dimensional conditions in a perfusion bioreactor to support maturation of human amnion epithelial stem cells into functional hepatocyte-like cells Sara Campinoti Received Received
  FRI-153 Dual roles of PSMP/MSMP in the progression of hepatic fibrosis and hepatocellular carcinoma Shaoping She Received Received
  THU-153 Stool microbiota, compared to salivary microbiota, show more extensive correlations with plasma metabolites in decompensated cirrhosis in a multinational cirrhosis cohort I. Jane Cox Received Received
  SAT-154 Knockdown of Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) accelerates liver regeneration and decreases chronic liver damage Viktoriia IAKOVLEVA Received Received
  FRI-154 NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model Sofia Mayans Received Received
  THU-154 The gut virome in non-alcoholic fatty liver disease: distinct changes in Phapecoctavirus composition in a human microbiota associated animal model Hau-Tak Chau Received Received
  FRI-155 Using qFibrosis analysis to predict disease and survival outcome of patients with hepatocellular carcinoma after curative treatment Elaine Chng Received Received
  SAT-155 Expression and function of axon guidance genes in the developing portal tract Lila Gannoun Received Received
  THU-155 Mitochondrial hyperactivation determines a transferable protective gut microbiota profile in metabolic-associated fatty liver disease development María Juárez-Fernández Received Received
  SAT-156 Patients with chronic liver diseases are at risk for diabetes even before development of cirrhosis Georgia Bale Received Received
  FRI-156 Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis Jong Suk Lee Received Received
  THU-156 Fecal transplant-related reductions in Alcohol intake from human to mice are associated with alterations in the intestinal but not liver or prefrontal cortex transcriptome Jasmohan S Bajaj Received Received
  THU-157 New insights from mapping of the mucosal gut microbiota in primary sclerosing cholangitis before and after liver transplantation Mikal Jacob Hole Received Received
  SAT-157 Characterization of bioengineered liver constructs using hepatoblast organoids (HBOs) and human liver extracellular matrix (ECM) 3D-platforms Margarita Papatheodoridi Received Received
  FRI-157 Direct anti-inflammatory and anti-fibrotic effects of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in thioacetamide-induced mouse model of liver injury and fibrosis Jung Kuk Kim Received Received
  THU-158 Designing a polymetabolic risk score for non-alcoholic steatohepatitis patients by differentiating their metabolic profiles from healthy controls Nadeen Habboub Received Received
  SAT-158 Novel avenue towards liver regeneration and treatment of acute and chronic liver diseases: safety and PK profile from a first-in human (FIH) clinical trial for HRX-0215 as first in class MKK4 inhibitor Wolfgang Albrecht Received Received
  FRI-158 Loss of bile salt export pump (BSEP/ABCB11) protects mice from development of carbon tetrachloride (CCl4) induced hepatic fibrosis Claudia Fuchs Received Received
  THU-159 Intestinal hyperpermeability in cirrhosis is predictive for survival and associated with distinct microbiome changes Vanessa Stadlbauer Received Received
  FRI-159 Large-scale multicenter study for the clinical utility of the non-invasive biomarkers Gas6 and soluble Axl in hepatocellular carcinoma, liver fibrosis and end-stage liver disease Wolfgang Mikulits Received Received
  SAT-160 In vivo loss-of-function studies unravel protein tyrosine phosphatase delta as a regulator of liver regeneration during metabolic liver disease Armando Andres ROCA SUAREZ Received Received
  FRI-160 Multispectral analysis of liver biopsies from patients with chronic hepatitis C reveals unique macrophage phenotypes and spatial interactions associated with fibrosis progression Omar Saldarriaga Received Received
  SAT-161 Integrated proteomics and metabolomics analysis reveals canonical and novel regulatory pathways linked to liver regeneration in living donor liver transplant (LDLT) Donors Gaurav Tripathi Received Received
  FRI-161 Neutrophil-specific NLRP3 activation triggers liver inflammation and fibrosis Benedikt Kaufmann Received Received
  THU-161 A nine-strain bacterial consortium improves portal hypertension and insulin signaling and delays non-alcoholic fatty liver disease progression in vivo Aurora Barbera Received Received
  THU-162 Duodenal permeability is associated with mucosal microbiota in compensated cirrhosis Patricia Bloom Received Received
  SAT-162 Regulation of extracellular Nicotinamide adenine dinucleotide in patients with liver fibrosis: new insights into conventional hepatobiliary parameters Can Kamali Received Received
  FRI-162 Imaging of fibrosis in metabolic associated liver disease by a radiolabeled affibody targeting PDGFRB Olivia Wegrzyniak Received Received
  THU-163 Impact of phenylacetic acid, a microbiota derived-metabolite, on hepatic endoplasmic reticulum-mitochondria interactions and steatosis Rémy Lefebvre Received Received
  FRI-163 Liver complications in greek patients with sickle cell disease: a multicenter retrospective analysis from eight thalassemia and sickle cell units across Greece Konstantinos Manganas Received Received
  FRI-164 Hemodynamic, molecular, and histological characterization of a toxic liver fibrosis regression model Philipp Knigshofer Received Received
  SAT-164 Embryogenesis of human fetal liver at various stages of gestation: a histomorphometric study Pooja Bhadoria Received Received
  THU-164 Dynamics of the gut-liver axis in rats with varying fibrosis severity Hongyan Xiang Received Received
  SAT-165 Generation of universal low-immunogenic human cholangiocyte organoids for treatment of cholangiopathies Sandra Petrus-Reurer Received Received
  FRI-165 The upper limit of normal of alanine aminotransferase (ALT) in diagnosing liver disease and fibrosis by the Intelligent Liver Function Test (iLFT) system Jeremy Lee Received Received
  SAT-166 Opposite PAR2 roles in liver regeneration from autoimmune or direct damage. Solving the conflict Gal Reches Received Received
  FRI-166 Inhibition of 11beta-hydroxysteroid dehydrogenase 1 relieves fibrosis through depolarizing of hepatic stellate cell in NASH Haeng Ran Seo Received Received
  FRI-167 Anti-fibrotic effects of microRNA-9-5p and microRNA-122 Dana Eidelshtein Received Received
  SAT-167 Chronic injury induces plasticity between cholangiocytes and hepatocytes in the human liver VASILEIOS GALANAKIS Received Received
  THU-167 Increased expression of programmed cell death ligand 1 and galectin 9 in transplant recipients who achieved tolerance after immunosuppression withdrawal Nguyen Hai Nam Received Received
  SAT-169 The hepatocellular vitamin D receptor regulates liver regeneration after partial hepatectomy Harendran Elangovan Received Received
  THU-169 Toll-like receptor 3 polymorphisms rs5743305 and rs3775291 affect innate immune responses in whole blood analyses Sophia Barkow Received Received
  SAT-170 Selective induction of macrophage RNF41 stimulates liver regeneration in hepatectomized healthy and fibrotic mice Alazne Moreno-Lanceta Received Received
  THU-170 IL-15 boots HBV-specific CD8 cell response by activated progenitor pool mitochondrial remodelling in on treatment e-Ag negative chronic hepatitis B Julia Peña Asensio Received Received
  FRI-170 MAIT cell inhibition promotes liver fibrosis regression by reprogramming macrophage phenotype Morgane MABIRE Received Received
  FRI-171 The LiverPRO score, a multivariable model for prediction of significant fibrosis in primary care: derivation, validation and comparison with FIB-4 and ELF-test in 5,000 study participants Katrine Lindvig Received Received
  THU-171 Mucosal-associated invariant T cells are rendered functionally exhausted within the tumour microenvironment in HCC in a cell-contact dependent manner Junika Pohl Received Received
  SAT-171 Generation of functional ductal organoid with biliary tree network in decelluarized liver scaffold Jiaxian Chen Received Received
  SAT-172 Molecular basis of hepatic differentiation of human bone marrow mesenchymal stem cell in vivo Dongyan Shi Received Received
  THU-172 Preclinical model for the study of immune responses specific for a hepatic-self-antigen Anas Cardon Received Received
  FRI-172 The protective effect of time-caloric restriction in liver fibrosis induced by nitrosamines in rat model Christian Molina-Aguilar Received Received
  FRI-173 Macrophage MerTK promotes a profibrogenic cross-talk with hepatic stellate cells via soluble mediators Mirella Pastore Received Received
  SAT-173 Dynamic alterations of metabolites revealed the vascularization progression of bioengineered liver Qian Zhou Received Received
  THU-173 Proximity labelling reveals potential cis interactions of CD52 glycoprotein counter-receptors on circulating CD4HLA-G regulatory T cells in acute decompensation of cirrhosis Tong Liu Received Received
  FRI-174 Comparative fibrosis-reducing activities of farnesoid X receptor (FXR), peroxisome-proliferator activated receptor delta (PPAR) and thyroid hormone receptor (THR) agonists in the carbon tetrachloride mouse model Edward Cable Received Received
  THU-174 Humoral and cellular immunity after vaccination against SARS-CoV-2 is reduced in patients with chronic liver disease Hevar Hamah Saed Received Received
  THU-175 Efficacy of branched-chain amino acid granules to restore innate immunity in cirrhosis-associated immune dysfunction: a randomized controlled trial Natthapat Rujeerapaiboon Received Received
  THU-176 The close correlation between sarcopenia and the phagocytic dysfunction in respond to bacterial pathogen Ecoli in cirrhotic patients NATTHAPAT RUJEERAPAIBOON Received Received
  FRI-176 The modulation of NADPH oxidases by tyrosol-derived phenolic compounds prevents hepatic fibrogenesis Daniela Gabbia Received Received
  THU-177 Heterologous SARS-CoV-2 vaccine triggers more humoral immune responses among patients with liver cirrhosis Apichat Kaewdech Received Received
  FRI-177 Exploring gender-related differences in liver fibrosis and regeneration through a new experimental carbon tetrachloride protocol in mice Katia Sayaf Received Received
  SAT-177 Pharmacologic inhibition of HSD17B13 is hepatoprotective in mouse models of liver injury Manuel Roqueta-Rivera Received Received
  SAT-178 Inhibition of NLRP3 inflammasome by GPR40 agonists Jeongwoo Park Received Received
  THU-178 Predictive immune biomarkers to safely discontinue nucleos(t)ide analogue treatment in HBeAg negative chronic hepatitis B (NUC-B study) Sandra Phillips Received Received
  FRI-178 Multicenter external validation of FIB-6: a novel, machine-learning, simple bedside score to rule out severe liver fibrosis and cirrhosis in patients with MAFLD Gamal Shiha Received Received
  FRI-179 A bioengineered approach to re-create and study the extracellular matrix-immune cell crosstalk in normal and fibrotic liver Sara Campinoti Received Received
  THU-179 MAIT-cells in blood are associated with a higher risk of infection in patients with cirrhosis Hannes Hagstrm Received Received
  SAT-179 Role of Monocyte chemoattractant protein-induced protein 1 in liver fibrosis and activation of hepatic stellate cells Natalia Pydyn Received Received
  FRI-180 Clinical and genetic factors associated with regression of fibrosis in ACLD after etiological therapy Yuly Paulin Mendoza Received Received
  SAT-180 The genomic landscape of IDH1 mutant intrahepatic cholangiocarcinoma: a multicentre comprehensive analysis margherita rimini Received Received
  THU-180 Fatty acids directly limit mucosal-associated invariant T cell effector function in non-alcoholic fatty liver disease Sebastian Deschler Received Received
  THU-181 Multimodal single cell analysis reveals the basis for butyrate induction of TNF?-secreting regulatory T cells Mo Atif Received Received
  FRI-181 Addressing the heterogeneity of fibrosis in liver biopsy specimens with qFibrosis -- a new paradigm for an old problem Elaine Chng Received Received
  SAT-181 Isolation of hepatocytes from various liver tissues by a novel, semi-automated perfusion technology Carsten Poggel Received Received
  FRI-182 Characterisation of the novel Galectin-3 inhibitor GB1107 on CCl4-induced liver fibrosis in mice Alison MacKinnon Received Received
  THU-182 COVID-19 vaccination in liver cirrhosis: safety and immune and clinical responses Maria Ins Canha Received Received
  FRI-183 Quantitative digital pathology of 3D human NASH models establish continuous scores to evaluate the antifibrotic effects of Selonsertib, Firsocostat and Resmetiron Louis Petitjean Received Received
  SAT-183 Ptpn1 deletion protects oval vells against lipoapotosis by favoring lipid droplet formation and dynamics Pilar Valdecantos Received Received
  SAT-184 Accurate detection of HBV splice variant DNA by using long-read sequencing Sanne Hulspas Received Received
  FRI-184 Etiology-independent fibrosis severity scoring by quantitative digital pathology image analysis Adam Watson Received Received
  THU-184 Patients with decompensated cirrhosis and liver transplant recipients demonstrate poor humoral and cellular immune response against COVID-19 vaccine Anand Kulkarni Received Received
  THU-185 Presence of cirrhosis in chronic liver disease patients associates with a lower immune response to COVID-19 vaccines - a multicenter european study Rui Castro Received Received
  FRI-185 Liver stiffness and autoimmune profile in a cohort of patients with systemic sclerosis Davide Di Benedetto Received Received
  SAT-185 The identification and characterization of novel bile acid-derived Farnesoid X Receptor agonists Dannielle Kydd-Sinclair Received Received
  THU-186 Heterogeneity of peripheral blood monocytes in patients with cirrhosis Anne Geng Received Received
  FRI-186 Performance of a p-SWE method implemented on a new ultrasound system for predicting advanced liver fibrosis Alexandru Popa Received Received
  SAT-186 SARS-CoV-2 induces pericyte procoagulant response associated with portal vein microthrombosis and intrapulmonary vascular dilations in fatal COVID-19 Luca Fabris Received Received
  THU-187 JAM-A is a multifaceted regulator in hepatic fibrogenesis, supporting LSEC integrity and stellate cell quiescence Jonathan Frederik Brozat Received Received
  FRI-187 Inhibition of tumour progression locus 2 (TPL2) halts the progression of liver fibrosis in a stringent long term choline deficient high-fat diet (CdHFD) rat model Milessa Afonso Received Received
  SAT-187 Dual ileal/renal-liver bile acid transporter inhibitors with different transporter ivity in vitro differentially increase faecal and urinary bile acid excretion in organic anion transporting polypeptide 1a/1b knockout mice in vivo Paris Fossa Received Received
  FRI-188 Evaluation of the antifibrotic effects of naringenin, asiatic acid and icariin by using precision-cut liver slices of mouse and human Ke Luo Received Received
  SAT-188 Integrated bile lipidome and meta-proteome analysis classifies lipid species and microbial peptides predictive of carcinoma of the gall bladder Nupur Sharma Received Received
  SAT-189 The effects of apurimic/apirimidinic endonuclease 1 as a sensitizer to sorafenib in hepatocellular carcinoma Nataliya Rohr-Udilova Received Received
  THU-189 Multi-omics analysis of human livers reveals variation in intrahepatic inflammation across chronic hepatitis B infection phases Andre Boonstra Received Received
  FRI-190 Multispectral imaging analysis of liver biopsies from patients with non-alcoholic steatohepatitis reveals enrichment of pathogenic macrophage phenotypes associated with disease progression Joseph Gosnell Received Received
  THU-190 Liver cirrhosis and cirrhosis etiology impacts the circulating immune mediators of early stage hepatocellular carcinoma Andre Boonstra Received Received
  THU-191 Ebola virus infection promotes reduced gene expression of antigen presentation molecules in hepatic CD68 macrophages in cynomolgus macaques Timothy Wanninger Received Received
  SAT-191 Soluble guanylyl cyclase expression and signaling in different types of liver fibrosis Ksenia Brusilovskaya Received Received
  FRI-191 Diabetes, but not prediabetes, is associated with significant liver fibrosis Won Sohn Received Received
  FRI-192 Lysophosphatidylserine may stimmulate liver fibrosis Takako Nishikawa Received Received
  SAT-192 Impact of maternal obesity on liver disease in the offspring: a comprehensive transcriptomic analysis and validation of results Beat Moeckli Received Received
  THU-192 Plasmalemma vesicle-associated protein expression is driven by senescent cell-endothelial crosstalk and shapes the immune landscape in chronic liver disease Alex Wilkinson Received Received
  SAT-193 Liver directed in utero AAV gene therapy for maple syrup urine disease in a neonatal lethal murine model Kate Mullany Received Received
  FRI-193 Quantitative assessment of liver fibrosis in NASH patients Luong Ruiz Received Received
  THU-193 Dysfunctional liver-resident CXCR6 CD8 T cells during persistent viral liver infection Miriam Bosch Received Received
  THU-194 Fate of HDV-specific CD8 T cells during bulevirtide monotherapy in patients with chronic hepatitis delta Valerie Oberhardt Received Received
  FRI-194 Second harmonic generation microscopy can quantify and subclassify early stages of NASH fibrosis progression: data from a screen-failure cohort of a NASH phase 2 study Philip OGorman Received Received
  SAT-194 Patient-derived hepatocellular carcinoma organoids as predictors of Treatment Response kyungjoo cho Received Received
  THU-195 Increased ILT2 expression contributes to dysfunction of CD56dimCD16NK cells in chronic hepatitis B virus infection Yingzhi Zhang Received Received
  SAT-195 Dissecting A-to-I RNA editome of liver macrophages in non-alcoholic fatty liver disease Achilleas Fardellas Received Received
  SAT-196 Restoring bone marrow hematopoietic stem cells (BM-HSC) reserve augments regression of fibrosis and regeneration in animal model of cirrhosis Nidhi Nautiyal Received Received
  THU-196 Elevated serum bilirubin levels and aminotransferases are associated with immuno-modulatory and suppressive subsets in pregnant females with intrahepatic cholestasis and hepatitis E virus infection Anoushka Saxena Received Received
  FRI-196 Endothelin receptor A antagonist functionalized magnetic nanoparticles as a promising approach for the treatment of liver fibrosis Marit ten Hove Received Received
  SAT-197 Human resident liver macrophages protect against metabolic stress in obesity Emelie Barreby Received Received
  FRI-197 3D human NASH model as a screening-based discovery approach for ing and prioritizing drug candidates Radina Kostadinova Received Received
  THU-197 Classification of HCV-specific CD8 T cells by the differential expression pattern of Slamf6 and CD69 predicts that the majority of cells are rather preterminally versus terminally exhausted regardless of disease stage Maximilian Knapp Received Received
  SAT-198 Reversal of epithelial-mesenchymal transition in a cholangiocarcinoma cell line by genetic targeting of sulfatide synthesis Gloria Alvarez Sola Received Received
  THU-198 TAPBPR shapes the hepatitis B immunopeptidome presented on HLA class I molecules Ricky Sinharay Received Received
  FRI-198 Investigating the function of Endothelial-To-Mesenchymal Transition during liver fibrogenesis using a Liver-On-A-Chip platform Neil Dufton Received Received
  FRI-199 Discovery of AMS-III-1086, a novel LPA1 antagonist for the treatment of liver fibrosis and liver cirrhosis Jung-Hee Kim Received Received
  THU-199 Phenotypes of NK cells and the activation profile of T cells in the early stages of alcohol liver diseases paola zuluaga blanco Received Received
  SAT-199 Unravelling the circadian transcriptome and epigenome of the human liver ATISH MUKHERJI Received Received
  SAT-200 Single-cell dynamics of interacting mesenchymal and leukocyte populations in advanced NASH Kamilla Hejn Received Received
  FRI-200 Integrated spatial-temporal mathematical liver lobule model for simulation of fibrotic wall formation Steven Dooley Received Received
  THU-200 A spatio-temporal map of malaria infected mouse liver Franziska Hildebrandt Received Received
  SAT-201 Dysregulated glutamine metabolism in intrahepatic cholangiocarcinoma: a perspective for targeted therapy Michela Anna Polidoro Received Received
  FRI-201 Telomerase-null mice display defective immune activation following the induction of liver fibrosis with S. mansoni Willian Gomes Received Received
  FRI-202 Multiplexed digital spatial protein profiling reveals potential non-invasive biomarkers to predict advanced fibrosis Chang Min Kim Received Received
  FRI-203 Sex and diagnosis-specific differences in liver elastography and attenuation Zhi Xin Tan Received Received
  SAT-203 Mcpip1 fl/fl LysM Cre mice as an animal model of TNFa-dependent liver endothelial cell dysfunction in humans with chronic inflammation Jerzy Kotlinowski Received Received
  SAT-204 Peroxisome proliferator activated receptor gamma regulates patatin-like phospholipase domain-containing protein 3 in adipocytes in vitro and in vivo in a mouse model of nonalcoholic steatohepatitis Emmanuel Dauda Dixon Received Received
  FRI-204 Progression of liver disease among patients with a new diagnosis of protease inhibitor ZZ alpha-1 antitrypsin deficiency Ed Marins Received Received
  FRI-205 Perihepatic implantation of matrix-embedded endothelial cells reduce inflammation and collagen deposition in fibrotic mice Mireia Medrano-Bosch Received Received
  SAT-205 Animal variants of sodium-taurocholate co-transporting polypeptide permitting hepatitis B virus infection Fuwang Chen Received Received
  SAT-206 Cholangiorcarcinoma-on-chip: a platform for 3D liver tumour model Michela Anna Polidoro Received Received
  FRI-206 LncRNA XR_592974.2 and circRNA _2599 regulated hypoxic stress response in hepatic stellate cells by targeting the miRNA-145/JMY/P53 pathway Dan Zhou Received Received
  SAT-207 Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase Hang Lam Li Received Received
  FRI-207 Magnetic resonance elastography (MRE) demonstrate the strongest correlation with digital pathology and NASH CRN fibrosis assessments, compared to transient elastography and other assessed non-invasive tests (NITs) Miljen Martic Received Received
  SAT-208 CRISPR perturbation in iPSC-derived hepatic stellate cells reveals role for TNF-driven interferon response in chronic liver disease Kelly Haston Received Received
  SAT-209 Regulation of cholangiocyte ciliogenesis by soluble adenylyl cyclase Hang Lam Li Received Received
  FRI-209 Selectivity matters: Novel ROCK2 inhibitor down-regulates established liver fibrosis via concurrent of targeting inflammatory, fibrotic and metabolic pathways Alexandra Zanin-Zhorov Received Received
  SAT-210 Signal transducer and activator of transcription 3 (STAT3)-driven hepatic transcriptional changes are indicative of a shift from immune tolerance to immune activation in chronic hepatitis B virus (HBV) infection Jinglin Tang Received Received
  FRI-210 Aldafermin rebalances collagen turnover in patients with NASH and liver fibrosis in the ALPINE 2/3 study Lei Ling Received Received
  SAT-211 Polymeric nanomicelles formulation of LY2157299-Galunisertib improves therapeutic outcome by greater reducing fibrosis and ameliorating fatty degeneration in a CCL4-induced hepatic-fibrosis rat-model Marco Fidaleo Received Received
  SAT-212 3D bioprinted hepatocyte and mesenchymal stem cell spheroids as a cell therapy for liver disease. Sam Wadsworth Received Received
  SAT-213 Fibroblast growth factors are therapeutic targets for radiofrequency ablation induced tumorigenesis Aurelia Markezana Received Received
  SAT-214 Glycine ameliorates paracetamol-induced liver injury in non-alcoholic fatty liver disease by supporting glutathione biosynthesis Alia Ghrayeb Received Received
  FRI-214 Use of the enhanced liver fibrosis test to risk stratify patients in the intelligent liver function test pathway: ruling out cirrhosis and advanced fibrosis Madeline Pearson Received Received
  FRI-215 Comparison of CT, blood test, elastometry and their combination for non-invasive staging of liver fibrosis Paul Calès Received Received
  SAT-215 Hepatocyte-specific deletiton of the anti-apoptotic Mcl-1 in mice induces polyploidization, mitotic erros and chromosomal instability. Laure-Alix Clerbaux Received Received
  SAT-216 Hepatic inflammation elicits production of proinflammatory netrin-1 through exclusive activation of translation Romain BARNAULT Received Received
  FRI-216 Reliability criteria of non-invasive tests for liver fibrosis Paul Calès Received Received
  SAT-217 A meta-analysis to identify novel candidate genes in the development of hepatocellular carcinoma Andrew Walakira Received Received
  FRI-217 Metabolomic profiling of capillary dry blood samples for the differential diagnoses of hepatocellular carcinoma and liver diseases Philipp Brunnbauer Received Received
  THU-217 Reducing the risk of liver cirrhosis and hepatocellular carcinoma after treatment for smoking cessation in patients with chronic hepatitis B or C infection: a 12-year follow-up study Yuan Tsung Tseng Received Received
  FRI-218 Stable rates of cirrhosis diagnosed by Fibroscan despite changing trends in liver disease epidemiology: a single centre retrospective cohort study Joan Ericka Flores Received Received
  THU-218 Testing coverage and strategy required to sustain Hepatitis C elimination in an injecting network of people who inject drugs: a network-based model RYan Buchanan Received Received
  FRI-219 Comparative assessment of noninvasive methods (NIMs)- LIVERFASt, liver stiffness measurement (LSM) with transient elastography (TE, Fibroscan) ELF and FiB-4 - in a prospective cohort with chronic liver diseases (CLD) from a tertiary liver center Mona Munteanu Received Received
  THU-219 Hepatocellular carcinoma screening trends in individuals with cirrhosis in North Carolina Christine Hsu Received Received
  THU-220 Cost- effectiveness evaluation of the hepatitis C elimination strategy in Cyprus in the era of affordable direct-acting antivirals Ilias Gountas Received Received
  FRI-220 Diagnostic accuracy of non-invasive imaging modalities for the diagnosis of liver cirrhosis compared to histological assessment in a clinical setting Mira Thing Received Received
  FRI-221 Use of Fibrosis-4 (FIB-4) in liver fibrosis screening: which thresholds to choose? denis ouzan Received Received
  THU-221 Rethinking the management of chronic hepatitis B in the context of rural sub-saharan Africa: results from a social justice mixed methods study in rural Senegal (the AmBASS-PeCSen study) Marion Coste Received Received
  THU-222 Global survey of healthcare workers attitudes to treatment of chronic hepatitis C infection in children and adolescents Farihah Malik Received Received
  FRI-222 Plasma cell-free DNA methylation as biomarker for hepatocellular carcinoma María Gárate-Rascón Received Received
  THU-223 Impact of community-based campaign in United States to increase hepatitis B virus screening and linkage to care among Asian immigrants from high endemic countries Sung Kwon Received Received
  FRI-223 A derivation and validation study of paired liver and plasma proteomics in 659 individuals reveals circulating biomarkers for alcohol-related liver disease Maja Thiele Received Received
  THU-224 The prognostic implications of liver function test abnormalities in patients admitted to hospital with COVID-19 Raza Malik Received Received
  FRI-224 Development and validation of a hepatic vascular geometrical model for noninvasive diagnosis of clinically significant portal hypertension in cirrhosis (CHESS1802) Chengyan Wang Received Received
  THU-225 A novel prognostic model including liver function parameters accurately predicts 30-day mortality in patients admitted with COVID-19 Raza Malik Received Received
  FRI-225 The diagnostic accuracy of ElastQ 2-D shear wave elastography for liver fibrosis risk assessment in a mixed etiology, multinational cohort David JM BAUER Received Received
  FRI-226 Machine learning models for prediction of severe portal hypertension in patients with compensated cirrhosis Oleksandr Petrenko Received Received
  THU-226 Low health literacy is associated with higher healthcare service utilisation and costs among patients with cirrhosis Elizabeth Powell Received Received
  FRI-227 Reproducibility and applicability of spleen stiffness measurement by vibration controlled transient elastograghy in patients with and without chronic liver disease Giulia Francesca Manfredi Received Received
  THU-227 A modelling approach to estimate alcohol-related liver morbidity and mortality in France Claire Delacte Received Received
  THU-228 A model to predict drinking population at-risk of liver disease in France: a tool for decision-making public health policies Claire Delacte Received Received
  FRI-228 Validation of the continuous controlled attenuation parameter (CAPc) using the MRI-PDFF as reference Anne LLORCA Received Received
  FRI-229 A novel non-invasive index for the prediction of liver fibrosis in chronic hepatitis B patients with concurrent nonalcoholic fatty liver disease Jie Li Received Received
  THU-229 Blood donors in Europe have substantially higher risk of exposure to HEV than in North America: results from a systematic review and meta-analysis Annika Wolski Received Received
  SAT-229 Outcomes of living liver donors are worse than those of matched healthy controls: nationwide cohort study Jong Man Kim Received Received
  THU-230 A population based-study of rates and trends of hepatitis C in immigrants and the Canadian-born in Quebec, Canada, 1998-2018 Ana Maria Passos-Castilho Received Received
  FRI-230 Comparison between two 2D-SWE techniques using transient elastography as a reference method for liver stiffness assessment Radu Cotrau Received Received
  SAT-230 Pretransplant changes in serum protein glycosylation relate to risk of HCC recurrence after liver transplantation and provide a potential prognostic biomarker: a proof-of-concept study Xavier Verhelst Received Received
  THU-231 HBV screening in west african migrant community and faith-based organizations increases HBV vaccination among this high-risk population in greater Barcelona, Spain Camila A Picchio Received Received
  SAT-231 Liver transplantation for complications of hepatoportal sclerosis Andrew Keaveny Received Received
  FRI-231 Shear wave elastography is a useful and accurate tool to triage patients with acute liver failure syndromes Francesca M Trovato Received Received
  FRI-232 A novel simple and reliable 2D-shear wave elastography (SWE) and ultrasound-guided coefficient attenuation parameter (SCAP) technique for patients with chronic liver disease Christiane Stern Received Received
  THU-232 Community-based HBV testing among west african migrants in greater Barcelona, Spain increases linkage to specialist care and vaccination: the HBV-COMSAVA model Camila A Picchio Received Received
  SAT-232 Discordance in categorization of acute-on-chronic-liver-failure in the national transplant database Brian Lee Received Received
  SAT-233 Humoral response to 2-dose BNT162b2 mRNA vaccine for COVID-19 in liver transplant recipients Valentina Cossiga Received Received
  THU-233 The impact of COVID-19 pandemic control measures on HCV treatment initiation in British Columbia, Canada Naveed Janjua Received Received
  FRI-234 Dynamics of liver stiffness predicts hepatocellular carcinoma and ascites occurrence in patients with hepatitis C virus related cirrhosis treated with direct-acting antiviral agents Alberto Nicoletti Received Received
  THU-234 Negative impact of COVID-19 infection related to life disruption events and health scores on patients with chronic liver disease Carey Escheik Received Received
  SAT-234 A predictive model for mortality within one year of liver transplantation at the time of wait-listing for transplant: a novel approach using machine learning algorithms in a large US multi-ethnic cohort Sripriya Balasubramanian Received Received
  SAT-235 Monitoring patients with anti HBs trough levels can minimise hepatitis B immune globulin therapy after liver transplant Erica Nicola Lynch Received Received
  FRI-235 The concordance within one blood test improves reliability evaluation of liver fibrosis Paul Calès Received Received
  THU-235 Associations of food insecurity and fast-food consumption with diet quality in adults with nonalcoholic fatty liver disease in a large population-based U.S. cohort Ani Kardashian Received Received
  SAT-236 Formal referral networks optimise patient ion for liver transplantation Oliver Tavabie Received Received
  THU-236 Implementation of HCV screening in the 1969-1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy Roberta DAmbrosio Received Received
  FRI-236 Novel and accurate measurement of differential protease activity in diagnosed HCC patients compared to non-HCC cirrhotic patients Amit Singal Received Received
  FRI-237 FIB-4 predicts severe hematological toxicity and 6-month mortality in older patients with cancer: ELCAPA-LIVER. Victoire De Salins Received Received
  SAT-237 Efficacy and safety of SARS-CoV-2 vaccination in liver transplant recipients Lucy Meunier Received Received
  THU-237 Real life pooling of plasma samples for hepatitis C RNA detection as a screening strategy of hepatitis C active chronic infection Federico Garcia Garcia Received Received
  FRI-238 The main thing is to be alive - exploring patients experiences with weight gain after liver transplantation: a qualitative study Sonja Beckmann Received Received
  SAT-238 Immunogenicity and safety of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA SARS-CoV-2 vaccine in liver transplant recipients: a prospective study Supachaya Sriphoosanaphan Received Received
  THU-238 Epidemiology of hepatocellular carcinoma in Portugal Mario Jorge Silva Received Received
  THU-239 Zero C hospital project: an innovative screening and referral model in hospitalized patients at different divisions valerio rosato Received Received
  FRI-239 Development of a nurse led hepatology ambulatory review service Bryony Butler Received Received
  SAT-239 Recurrence of primary sclerosing cholangitis after liver transplantation: a French cohort study including 571 patients Florian Veyre Received Received
  THU-240 LINK-B: a hepatitis B program to test and link to care patients lost of follow up Anna Feliu-Prius Received Received
  FRI-240 Development of a nurse led daycase abdominal paracentesis service Victoria Wharton Received Received
  THU-241 Testing for liver disease in primary case: fibrosis first Ian Rowe Received Received
  FRI-241 Implementing a cirrhosis order set: a qualitative analysis of provider-identified barriers and facilitators Ashley Hyde Received Received
  SAT-241 Perinatal outcomes in liver transplant patients-possible positive effect of aspirin prophylaxis Marius Braun Received Received
  FRI-242 Quality of life in patients with advanced cirrhosis. Relationship with the development of complications Ana Belén Rubio Received Received
  SAT-242 Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients Aitor Odriozola Herrán Received Received
  THU-242 Hepatitis C care cascade analysis among adult women in Georgia Ketevan Stvilia Received Received
  THU-243 Progress in HCV screening in the national hepatitis C elimination program in Georgia during the COVID-19 pandemic, 2019-2021 Maia Tsreteli Received Received
  FRI-243 Effects of the COVID-19 pandemic on the activity of an advanced practice nurse clinic on liver cirrhosis Martina Pérez-Guasch Received Received
  SAT-243 Early post liver transplant rescue treatment with sofosbuvir/velpatasvir/voxilaprevir in patients experienced to NS5A-inhibitors Margherita Saracco Received Received
  FRI-244 STIGMATIZATION IS COMMON IN PATIENTS WITH METABOLIC ASSOCIATED FATTY LIVER DISEASE AND CORRELATES WITH QUALITY OF LIFE Marta Carol Perdiguer Received Received
  THU-244 Could a multi-target blood test make hepatocellular carcinoma surveillance programs more effective? A modelling-based virtual trial Jagpreet Chhatwal Received Received
  SAT-244 Inclusion of body composition parameters in MELD score leads to optimization of predictive performance in patients with cirrhosis Maryam Ebadi Received Received
  FRI-245 Effect of e-health-based interventions on weight loss in patients with NAFLD: a systematic review and meta-analysis of randomized controlled trials Ferya Celik Received Received
  SAT-245 Long-lasting seropositivity after anti SARS-CoV-2 vaccination in pre liver transplant patients Alberto Calleri Received Received
  THU-246 A model, screen test and treat hepatitis C elimination project among under-served communities in Islamabad-the federal capital of Pakistan Hassan Mahmood Received Received
  FRI-246 Role of mutant alpha-1-antitrypsin in determining liver cell fate during embryonic development and in HCC origin Francesco Annunziata Received Received
  SAT-246 The outcome of living donor versus deceased donor liver transplantation for hepatocellular carcinoma: a systematic review and meta-analysis Beshoy Elkomos Received Received
  THU-247 Hepatitis B and hepatitis C testing practices and seroconversions among dialysis facilities in Georgia Maia Butsashvili Received Received
  SAT-247 Impact of gender on survival of hepatocellular carcinoma Chaonan Jin Received Received
  THU-248 Innovative linkage model to re-engage loss-to-follow-up individuals in the national hepatitis C elimination program of Georgia Vladimer Getia Received Received
  FRI-248 In vitro rescue of nonsense variations by drug-induced readthrough of premature termination codons in progressive familial intrahepatic cholestasis type 2 Martine LAPALUS Received Received
  SAT-248 Effectiveness of MRI methods in the assessment of hepatic steatosis in living liver donors Digdem Kuru z Received Received
  SAT-249 Long-term outcomes of donation after cardiac death and living donor liver transplant for primary sclerosing cholangitis Dilip Moonka Received Received
  FRI-249 Search for biomarkers and prognostic indicators of liver degeneration in glycogen storage disease type Ia Roberta Resaz Received Received
  THU-249 Combined COVID-19 vaccination and HIV and hepatitis C virus screening intervention for high-risk populations at a mobile testing unit in Madrid, Spain Jeffrey Lazarus Received Received
  SAT-250 Patients with acute-on-chronic liver failure have significantly greater healthcare resource utilization after liver transplantation Vinay Sundaram Received Received
  THU-250 A model to eradicate HCV in undocumented migrants and low-income refugees in Italy Nicola Coppola Received Received
  FRI-250 Alpha-1 antitrypsin (AAT) augmentation therapy and liver phenotype in individuals with homozygous PiZ AAT mutation (PiZZ genotype) Malin Fromme Received Received
  THU-251 Enhancing the cascade of hepatitis C care in community-recruited high-risk people who inject drugs during the COVID-19 pandemic: the Alexandros program Angelos Hatzakis Received Received
  FRI-251 Impact of acute hepatic porphyria attack frequency on patient-reported outcomes: results from the porphyria worldwide patient experience research (POWER) study Amy Dickey Received Received
  SAT-251 Use of statins after liver transplantation is associated with improved survival: results of a nationwide study Chiara Becchetti Received Received
  FRI-252 Large-scale, multi-centric prospective validation of the polycystic liver disease complaint-specific assessment (POLCA) Antoon Billiet Received Received
  SAT-252 Liver transplantation for hepatocellular carcinoma with extended criteria: performance and applicability of the AFP score after official adoption by the French Organ Sharing Organization ABM: 5-year outcomes Christophe Duvoux Received Received
  THU-252 SVR4 and SVR12 monitoring by using dried blood spot test: is it the best alternative for people who use drugs? Jeffrey Lazarus Received Received
  SAT-253 Tacrolimus drug exposure level in the first year after liver transplantation is an independant risk factor for de novo malignancy in patients transplanted for alcohol-related liver disease Benedict Vanlerberghe Received Received
  THU-253 Collateral benefit of Georgia national hepatitis C elimination program - improving blood transfusion safety in the country of Georgia Maia Alkhazashvili Received Received
  FRI-253 Improvements in quality of life in odevixibat responders and nonresponders: an analysis of pooled data from the PEDFIC 1 and PEDFIC 2 studies Cara L. Mack Received Received
  SAT-254 SARS-CoV-2 vaccination in liver transplant recipients: factors affecting immune response and refusal to vaccine Maciej K. Janik Received Received
  THU-254 Outcomes of a community led comprehensive HCV and HBV care provision model, including same-day test and treat to facilitate micro-elimination of HCV among people who inject drugs in Manipur, India Rajkumar Nalinikanta Received Received
  FRI-254 Total, primary, and secondary serum bile acid changes and pruritus improvement during odevixibat treatment in patients with progressive familial intrahepatic cholestasis Henkjan J. Verkade Received Received
  SAT-255 The effect of clinicopathologic findings of hepatocellular carcinoma on posttransplant survival: a multcenter cohort from TASL liver transplantation special interest group Murat Akyildiz Received Received
  FRI-255 Changes in hepatic parameters, growth, sleep, and biochemical markers with odevixibat treatment across patients with various types of progressive familial intrahepatic cholestasis Paris Fossa Received Received
  THU-255 A novel hepatitis C intervention in Denmark to test and treat people who inject drugs Jeffrey Lazarus Received Received
  SAT-256 Utility and prognostic value of diagnosing metabolic dysfunction-associated fatty liver disease in patients undergoing liver transplantation for alcohol-related liver disease Benedict Vanlerberghe Received Received
  THU-256 Peer-led hepatitis C services reach poorly served populations at scale: a model for tackling health inequalities Leila Reid Received Received
  FRI-256 Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment Paris Fossa Received Received
  THU-257 Cost-effectiveness of integrated treatment for hepatitis C virus among people who inject drugs in Norway: an economic evaluation of the INTRO-HCV trial Aaron G. Lim Received Received
  FRI-257 Longitudinal follow-up data on adults with classic, severe alpha-1 antitrypsin deficiency (PiZZ genotype) Malin Fromme Received Received
  SAT-257 Severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) specific cellular and humoral immunity in Corovavirus Disease-2019 (COVID-19) convalescence after liver transplantation - a prospective six month follow up Theresa Kirchner Received Received
  SAT-258 A third dose of the BNT162b2 mRNA vaccine significantly improved immune response among liver transplant recipients Yana Davidov Received Received
  THU-258 Characterization of HCV recent infections and re-infections among high-risk population from Georgia using global hepatitis outbreak and surveillance technology Adam Kotorashvili Received Received
  FRI-258 Gender dependent neurological and hepatic improvement in Wilson disease patients treated with Trientine dihydrochloride: post hoc results from a prospective study Larissa Wijnberg Received Received
  FRI-259 Efficacy and safety of odevixibat over 72 weeks of treatment in patients with progressive familial intrahepatic cholestasis Richard J. Thompson Received Received
  SAT-259 Everolimus combined with low-dose tacrolimus controls histological graft injury and liver fibrosis as sufficiently as high-dose tacrolimus combined with mycophenolate after liver transplantation Fabian Dranicki Received Received
  THU-259 Prevalence and predictors of significant liver fibrosis : a population-based cross-sectional study Aayushi Rastogi Received Received
  FRI-260 In vitro rescue of the bile acid transport function of some ABCB11 variants by CFTR potentiators: a targeted pharmacotherapy in progressive familial intrahepatic cholestasis type 2 Elodie Mareux Received Received
  SAT-260 The portrait of adult liver transplant recipients in the United States from 2002-2020 Carey Escheik Received Received
  THU-261 Prognostic value of liver function test for COVID-19 hospitalized patients with respiratory disease Carlos Alventosa Mateu Received Received
  FRI-261 Plasma-based proteomics profiling of patients with Wilsons disease Jie Su Received Received
  SAT-261 Heterologous regimen viral-vector/mRNA produces significantly higher SARS-CoV-2 humoral response than homologous viral-vector and inactivated vaccines in liver transplant recipients Manuel Mendizabal Received Received
  FRI-262 Management of hepatic sarcoidosis - multicentric approach Janina Sollors Received Received
  THU-262 Effectiveness of COVID-19 viral vector vaccine Ad.26.COV2.S vaccine and comparison with mRNA vaccines in patients with cirrhosis Binu John Received Received
  SAT-262 Evolution of pretransplant cardiac risk factor burden and major adverse cardiovascular events in liver transplant recipients over time Claire Harrington Received Received
  SAT-263 Retransplantation (reLT) outcomes of patients who were initially transplanted for ACLF gandhi lanke Received Received
  THU-263 Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study massimo iavarone Received Received
  FRI-263 Plasma proteomics identifies hepatic steatosis and sex differences in 2,147 children and adolescents Lili Niu Received Received
  SAT-264 The ratio of Activin A and Follistatin-related gene allows prediction of posthepatectomy liver failure and postoperative morbidity in patients prior to liver surgery Jonas Santol Received Received
  THU-264 The protective role of dairy protein on sarcopenic obesity in middle-aged and older women: a community-based, 12-year, prospective cohort study Jun-Hyuk Lee Received Received
  FRI-264 Pregnancy outcomes in women with Budd Chiari syndrome: a single center experience Sagnik Biswas Received Received
  THU-265 Detection of microplastics in cirrhotic liver tissue Thomas Horvatits Received Received
  FRI-265 New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination - a vascular liver disease group (VALDIG) initiative Raoel Maan Received Received
  SAT-265 Derivation of a cardiac risk index for use in liver transplantation for non-alcoholic steatohepatitis Paul Levy Received Received
  THU-266 Patient Navigators: an innovative approach to improve hepatitis c case finding leveraging existing human immunodeficiency virus service delivery models to reach last mile patients in Nasarawa State, Nigeria Chukwuemeka Agwuocha Received Received
  FRI-266 Abdominal wall hernia is a frequent complication of polycystic liver disease and associated with hepatomegaly Thijs Barten Received Received
  SAT-266 The prognostic effect of adequate lymphadenectomy in clinically node-negative patients undergoing liver resection for intrahepatic cholangiocarcinoma Carlo Sposito Received Received
  THU-267 The Community Pop-Up Clinic (CPC): a unique strategy to achieve HCV elimination in the inner city Brian Conway Received Received
  FRI-267 MR-derived metrics have utility in identifying paediatric patients with stable autoimmune hepatitis Piotr Pawliszak Received Received
  SAT-267 Impact of MELD 3.0 versus MELD-Na in patients with renal dysfunction Allison Kwong Received Received
  SAT-268 Sustainability of humoral immunity induced by the SARS-CoV-2 vaccine and response to booster dose among Liver Transplant recipients Liane Rabinowich Received Received
  FRI-268 Development and validation of a novel ICP-MS method to quantify different copper species in human plasma from patients with Wilson disease Ryan Pelto Received Received
  THU-268 Age, gender and region-specific HBsAg and anti-HCV seroprevalence in Ghana: a nationwide hospital based cross-sectional study Yvonne Ayerki Nartey Received Received
  THU-269 The elimination of hepatitis C in the cherokee Nation: the impact of harm reduction Devin Razavi-Shearer Received Received
  SAT-269 Acute-on-chronic liver failure due to severe intrahepatic vaso-occlusion and recurrence of the intial disease: 2 major features in liver transplantation for severe sickle-cell-related hepatopathy Christophe Duvoux Received Received
  FRI-269 Quantitative magnetic resonance cholangiopancreatography identifies features of ductal disease change in primary sclerosing cholangitis: a prospective observational cohort study Liam Young Received Received
  SAT-270 Post-operative complications and short-term survival in obese cirrhotic patients undergoing liver transplantation Carmen Alonso Martin Received Received
  FRI-270 Age at diagnosis is associated with mortality in patients with hereditary hemochromatosis Clare Foley Received Received
  THU-270 Effectiveness of mRNA vaccines in patients with cirrhosis with rising prevalence of SARS-CoV-2 delta variant Binu John Received Received
  SAT-271 Impact of comorbidities on liver transplantation: a prospective and multicentric study Magdalena Salcedo Received Received
  THU-271 Epidemiology and management of hepatitis B and C in primary care in the Netherlands - data from the Rijnmond primary care database Sylvia Brakenhoff Received Received
  FRI-271 Development of Hepatoblastoma organoids as a patient-derived ex-vivo system Laura Zanatto Received Received
  FRI-272 High rates of histological findings compatible with porto-sinusoidal vascular disease in patients with constantly elevated gamma-glutamyl transferase levels undergoing a liver biopsy Nicola Pugliese Received Received
  SAT-272 Liver transplant patients infection rate with SARS-CoV-2 is lower but depend upon the infection rate in the general population and have a better outcome Michal Cohen-Naftaly Received Received
  THU-272 Point of care testing for hepatitis C in the priority settings of mental health, prisons and drug and alcohol facilities Catherine Ferguson Received Received
  FRI-273 Plasma metabolomics and machine learning characterizes metabolite signature capable of segregating patients with poor outcome in pediatric cirrhosis Babu Mathew Received Received
  THU-273 Association of novel lifestyle- and whole foods base inflammation scores with metabolic dysfunction-associated fatty liver disease: a population-based study among iranian adults Ehsaneh Taheri Received Received
  SAT-273 Sarcopenia predict complications after hepatic resection for primary hepatocellular carcinoma (HCC) in patients with advanced chronic liver disease (ACLD) and clinically significant portal hypertension (CSPH) Federico Ravaioli Received Received
  SAT-274 A comparison of hispanic living liver donor candidates approved and denied at a high-volume urban transplant center Dana Toy Received Received
  FRI-274 Experience of cholestatic pruritus emphasized by patients with PBC: results from the PBC Foundation app survey Chris Mitchell Received Received
  THU-274 Assessment of COVID-19 impact and response on hepatitis B virus and hepatitis C virus prevention and treatment from nationwide survey in Japan Md Razeen Ashraf Hussain Received Received
  FRI-275 Cancer risk in acute hepatic porphyria: a nationwide matched cohort study in 1,245 individuals Hannes Hagstrm Received Received
  THU-275 Knowledge, attitude and practice regarding COVID-19 vaccination among HCV infected patients in Georgia Lasha Gulbiani Received Received
  SAT-275 Liver transplantation in HIV infected subjects: a long-term single center experience Noemi Gualandi Received Received
  SAT-276 SARS-CoV-2 infection in liver transplant recipients - a single center case series from Romania Ioana-Alexandra Husar-Sburlan Received Received
  FRI-276 Innovative approach using clinical metagenomics for the diagnosis of non-elucidated liver disease Anna Sessa Received Received
  THU-276 CRIVALVIR-FOCUS: low HIV and chronic Hepatitis B and C infection prevalence among women in reproductive and sexual health services in Valencia, Spain Miguel Garcia Deltoro Received Received
  THU-277 mRNA COVID-19 vaccine effectiveness in liver transplant patients Muhammad Khan Received Received
  SAT-277 Liver transplantation for hepatocellular carcinoma: outcome and prognostic factors for recurrence Veronica Paon Received Received
  FRI-277 Accumulation of molybdenum in major organs following chronic oral administration of bis-choline tetrathiomolybdate in Sprague Dawley rats Kharmen Billimoria Received Received
  THU-278 Evaluation of global progress towards HBV and HCV elimination Sarah Blach Received Received
  SAT-278 The liver outcomes and equity (LOEq) index: neighborhood social determinants independently predict outcomes in liver transplantation Kali Zhou Received Received
  FRI-279 Liver fibrosis and fat by transient elastography in patients with Alpha-1 antitrypsin deficiency Hassaan Yousuf Received Received
  SAT-279 Prevalence, prognosis, clinical, biological and histological features of incidentally found hepatocellular carcinoma after liver transplantation bénédicte delire Received Received
  THU-279 The Impact of Vaccination on the Global and Regional Pediatric Prevalence of Hepatitis B from 1985-2022 Devin Razavi-Shearer Received Received
  FRI-280 Novel imaging feature in patients with porto-sinusoidal vascular disorder (PSVD) - radiological evaluation guiding diagnosis Georg Semmler Received Received
  THU-280 Feasibility and effectiveness of hepatitis C micro-elimination among 19 prisons of northern India Kanudeep kaur Received Received
  SAT-281 Long-term outcomes of liver transplantation (LT) using grafts from donors with active and chronic hepatitis B virus (HBV) infection: multi-center cohort study Sujin Gang Received Received
  THU-281 The impact of treatment and health policies for Hepatitis C Virus on hospitalizations in the last decade: data analysis of records of hospital discharge (SDO) at Italian national level Claudia Simonelli Received Received
  SAT-282 Safe use of hepatitis B surface antigen positive (HBsAg ()) grafts in liver transplantation (LT): a nationwide study based on KOTRY (Korean Organ Transplantation Registry) data Sujin Gang Received Received
  THU-282 Hepatitis B birth dose coverage remains dramatically low in The Gambia and has been disrupted by the COVID-19 pandemic Maud Lemoine Received Received
  FRI-282 The role of the mechanistic target of rapamycin (mTOR) in Alpha-1 Antitrypsin Deficiency Lisa Bewersdorf Received Received
  FRI-283 Cerebrotendinous xanthomatosis: long-term course in 5 patients and first description of a successful pregnancy management during therapy with chenodesoxycholic acid (CDCA) Jan Koehler Received Received
  SAT-283 A panel of three micro RNAs allows robust prediction of overall survival after liver resection David Pereyra Received Received
  THU-283 Hepatitis B prevalence and the impact of vaccination in Georgia: results from a nationwide serosurvey Nino Khetsuriani Received Received
  FRI-284 A rare genetic variant in the manganese transporter SLC30A10 and elevated liver enzymes in the general population Anne-Sofie Seidelin Received Received
  THU-284 Progress towards HCV elimination in the country of Georgia: Insights from modelling and national survey Josephine Walker Received Received
  SAT-284 Liver transplantation for primary sclerosing cholangitis and predictors of disease recurrence Julie Zhu Received Received
  FRI-285 A small molecule chaperone for alpha-1 antitrypsin deficiency-associated liver disease reduces liver polymer burden in the PiZ mouse model Britta Handyside Received Received
  SAT-285 Predictive factors of antibody response after anti-SARS-CoV-2 vaccine in liver transplant recipients Ilias Kounis Received Received
  THU-285 Measuring the alcohol related hospital burden in Ireland and the impact of Minimum Unit Pricing (MUP) Tobias Maharaj Received Received
  SAT-286 Immunotherapy before solid organ transplantation: an international transplant community-focused survey Tommy Ivanics Received Received
  THU-286 Is hepatic steatosis individually a risk factor for colorectal adenoma? Anuroop Yekula Received Received
  FRI-286 A melting pot of genetic variability in Wilsons disease - real world study from London, UK James Liu Yin Received Received
  SAT-287 Evaluating the predictive performance and transferability of machine learning-based prediction models using national liver transplant data registries Tommy Ivanics Received Received
  THU-287 No effect of HBsAg positivity on antibody response after COVID-19 vaccine Ganbolor Jargalsaikhan Received Received
  FRI-287 The alpha-1 antitrypsin PiZ allele is an independent risk factor for liver transplantation/death in patients with advanced chronic liver disease Lorenz Balcar Received Received
  FRI-288 Fontan associated liver disease: A cohort review into the prevalence of portal hypertension Hannah Donnelly Received Received
  SAT-288 Liver transplant recipients have a higher incidence of lung cancer than general population Jose Ignacio Herrero Received Received
  SAT-289 Survival benefit-based priority of liver transplantation in HBV-related acute-on-chronic liver failure Jun Li Received Received
  FRI-289 Senolytic therapies have a place in pediatric biliary cirrhosis Giulia Jannone Received Received
  THU-289 Evaluation of the clinical and economic value of sofosbuvir/velpatasvir (SOF/VEL) in patients with chronic hepatitis C in Spain during the last 5 years Raquel Domínguez-Hernández Received Received
  SAT-290 Social determinants of health and racial disparities in liver transplant: a nation wide analysis Mahmoud Mansour Received Received
  THU-290 The value of increased HCV testing and treatment strategies in Spain to achieve elimination goals Alon Yehoshua Received Received
  FRI-290 PNPLA3 rs738409 G allele increases the risk of liver cirrhosis in SERPINA1 MZ heterogygotes So&328;a Fra&328;ková Received Received
  SAT-291 Reduced neutralization efficacy against SARS-CoV-2 Omicron variant after third boost of mRNA BNT162 vaccine among liver transplant recipients Yana Davidov Received Received
  FRI-291 Patient experience of their Primary Biliary Cholangitis (PBC) management compared to clinical practice guidelines Chris Mitchell Received Received
  THU-291 National Hepatitis Elimination Profiles: Progress towards HBV and HCV elimination in five European countries Lindsey Hiebert Received Received
  THU-292 Economic investment and strategies to eliminate hepatitis C in Mexico Ellen Mooneyhan Received Received
  FRI-292 Evaluation of the clinical impact of the Ceruloplasmin variant p.Thr551Ile in liver cirrhosis Marlene Panzer Received Received
  FRI-293 Circulating miR-21 parallels the incidence of IBD in PSC patients André Santos Received Received
  SAT-293 Hepatic evaluation of patients with telomeropathies Olivia Portolese Received Received
  SAT-294 Third dose of SARS-COV2 mRNA-vaccine in liver transplant recipients: can it bridge the response gap? Raffaella Lionetti Received Received
  FRI-294 Hepatocellular Carcinoma in Fontan Associated Liver Disease: Uncharted Territory - Are We Doing Enough? Michael Christmas Received Received
  THU-294 Eliminating chronic hepatitis B in the Northern Territory of Australia through a holistic care package delivered in partnership with the community Jane Davies Received Received
  SAT-295 Protein-energy malnutrition is associated with worse outcomes in patients admitted for liver transplant: analysis of national inpatient sample Mahmoud Mansour Received Received
  THU-295 Hepatitis C prevalence and elimination in Pakistan; a bottom-up approach accounting for provincial variation Ellen Mooneyhan Received Received
  FRI-295 Are patients with Fontan-associated liver disease (FALD) appropriately screened for oesophageal varices? Queensland Quaternary adult congenital heart disease referral centre experience Anthony Bergin Received Received
  FRI-296 Primary liver malignancies in patients with Wilsons disease Rodolphe SOBESKY Received Received
  SAT-296 COVID Vaccination among Liver Transplant Recipients: A EASL - ESOT/ELITA - ILTS multi society survey Carmen Vinaixa Received Received
  THU-296 Association between immunosuppressants and poor antibody responses to inactivated SARS-CoV-2 vaccines in patients with autoimmune liver diseases hu li Received Received
  THU-297 Like what? You think I have that? - Impact of stigma on pharmacy-based identification and treatment of hepatitis C in Victoria, British Columbia Kellie Guarasci Received Received
  FRI-297 Defining the boundaries for stability in Wilson disease patients on maintenance chelation therapy: Lessons from the CHELATE Trial Michael Schilsky Received Received
  SAT-297 Does m-RNA Vaccination protect from Sars-Cov2 (asymptomatic) infection in liver transplant recipients? Ubaldo Visco Comandini Received Received
  SAT-298 Low dose interleukin-2 ively expands circulating regulatory T cells but fails to promote transplantation tolerance in humans Tiong Yeng Lim Received Received
  FRI-298 Precision-cut liver slices as an ex vivo model to assess impaired hepatic glucose production Kishore Alagere Krishnamurthy Received Received
  THU-298 Improved clinical and economic outcomes in an intensive care unit with a focus on hepatology through interprofessional cooperation between physicians, staff nurses, and pharmacists Schmid Stephan Received Received
  FRI-299 Interim 52-week analysis of immunogenicity to the vector capsid and transgene-expressed human FVIII in GENEr8-1, a phase 3 clinical study of valoctocogene roxaparvovec, an AAV5-mediated gene therapy for hemophilia A Britta Handyside Received Received
  THU-299 Need to implement the screening strategy to advance HCV elimination in Italy: a cost-consequences analysis Kristi Tata Received Received
  SAT-299 Clinical significance of three-dimensional printing of the portal venous system in patients with extrahepatic portal hypertension Binita Chaudhary Received Received
  SAT-300 Liver Transplantation (LT) and Ethnicity in the United States: The Impact of Non-alcoholic Steatohepatitis Carey Escheik Received Received
  THU-300 Evaluation of access to treatment for Hepatitis C: a large retrospective cohort from a tertiary care hospital in Turkey Merve Eren Durmus Received Received
  SAT-301 CAN ENDOTHELIAL BIOMARKERS BEFORE LIVER TRANSPLANTATION TOGETHER WITH CLASICAL CARDIOVASCULAR RISK FACTORS BE USEFUL TO PREDICT CARDIOVASCULAR RISK AFTER LIVER TRANSPLANTATION Victoria Aguilera Received Received
  THU-301 Hepatitis E Virus Capsid Antigen (HEV-Ag): a practical diagnostic biomarker in the HEV outbreak scenerio Simon Lytton Received Received
  THU-302 Bulevirtide is broadly active against all HDV genotypes expressing envelopes from HBV genotypes A-H and a large panel of clinical isolates Savrina Manhas Received Received
  FRI-302 Active case management to connect hepatitis C notifications to care and treatment in Australia (CONNECT study), a randomised controlled trial Tafireyi Marukutira Received Received
  SAT-302 Factors contributing to late evaluation in liver transplant candidates undergoing inpatient liver transplant evaluation Katherine Cooper Received Received
  SAT-303 CMV REACTIVATION IS ASSOCIATED WITH LOWER HEPATOCELLULAR CARCINOMA (HCC) RECURRENCE AFTER LIVER TRANSPLANTATION (LT) Victoria Aguilera Sancho Received Received
  FRI-303 Find out HCV patients: systematic study of 2013-2020 HCV files of a MDT viral hepatitis expert unit on the future of patients has made it possible to find out the lost ones and put them into treatment ANDRE JEAN REMY Received Received
  THU-304 Functionnal and mitochondrial dynamics alterations in patients with chronic hepatitis B and advanced fibrosis Dimitri Loureiro Received Received
  SAT-304 Managing HBV/HDV co-infection post liver transplant - Exploring a decade of experience Almuthana Mohamed Received Received
  FRI-304 Effectiveness of a central monitoring system for the continuum of care of hepatitis C in Brazil during COVID-19 pandemic Paulo Bittencourt Received Received
  THU-305 Dual antiviral activity of farnesyl transferase inhibitor on hepatitis D virus infection revealed by RT-ddPCR Eloi Verrier Received Received
  SAT-305 Durability of SARS-CoV-2 specific immune response following different primary prime-boost vaccine platforms and subsequent humoral response to booster dose among liver transplant recipients Supachaya Sriphoosanaphan Received Received
  FRI-305 Retrieval of HCV patients lost to follow-up as a strategy as a strategy for hepatitis C microelimination: results of a brazilian multicentric study Paulo Bittencourt Received Received
  THU-306 Characterization of circulating hepatitis B Virus RNAs in vitro and chronic hepatitis B patients Doohyun Kim Received Received
  SAT-306 Outcome of choledochal cysts with intrahepatic involvement (type IV-A) after extrahepatic cyst excision and roux-en-Y hepaticojejunostomy in adults Utpal Anand Received Received
  FRI-306 Reorganizing and simplifying HCV diagnosis and treatment in special populations during COVID pandemic and beyond Paolo Scivetti Received Received
  THU-307 Identification of shuttle protein hnRNPA1 as a modulating factor of circulating hepatitis B Virus RNAs release in chronic hepatitis B patients Hyoseon Tak Received Received
  FRI-307 The health economic outcomes of trial ACTG5360/MINMON Tannishtha Pramanick Received Received
  SAT-307 The impact of COVID-19 on the duration of the liver transplant process in patients presenting for inpatient liver transplant evaluation Katherine Cooper Received Received
  THU-308 Long-read sequencing of HCC samples reveals complete architecture of HBV integrations and chimeric mRNA isoforms associated with oncogenes Cameron Soulette Received Received
  SAT-308 Patients with polcystic liver disease have longer waiting times but better clinical outcomes following liver transplantation in the UK Matthew Gittus Received Received
  FRI-308 Hepatitis C treatment during the COVID-19 pandemic has similar efficacy with less resource utilization: analysis from the British Columbia HCV network Alnoor Ramji Received Received
  FRI-309 ELIMINATE - interim results of an Austrian HCV macro-elimination project Caroline Schwarz Received Received
  THU-309 Polymorphic analysis of bulevirtide sequence in PreS1 of large HBsAg across HBV genotypes A-H Roberto Mateo Received Received
  SAT-309 Missed referrals for liver transplant evaluation are associated with worse outcomes in patients needing inpatient liver transplant evaluation Katherine Cooper Received Received
  SAT-310 Nutritional intake after liver transplant: systematic review with meta-analysis and meta-regression Lynsey Spillman Received Received
  FRI-310 The korean hepatitis C virus care cascade in a tertiary institution: current status and changes in testing, link to care, and treatment Jonggi Choi Received Received
  SAT-311 Impact of muscle mass on survival of patients with Hepatocellular Carcinoma after liver transplantation beyond the Milan criteria Berend Beumer Received Received
  FRI-311 Macroeconomic assessment of overall and per-patient healthcare costs of Hepatitis C-infected patients in an integrated health system in the era of direct-acting antiviral therapy David Kaplan Received Received
  THU-311 Limited value of HBV-RNA levels for the prediction of relapse after discontinuation of nucleos(t)ide analogue therapy in HBe antigen negative chronic hepatitis B patients Valerie Ohlendorf Received Received
  FRI-312 Awareness of chronic hepatitis B and C among men who have sex with men (MSM): epidemiological survey and on-site screening Marie Coessens Received Received
  THU-312 A versatile small animal immunocompromised model for chronic hepatitis E Siddharth Sridhar Received Received
  FRI-313 Predictive factors for lost to follow-up pre and post-hepatitis C treatment: data from the British Columbia hepatitis C virus network Alnoor Ramji Received Received
  THU-313 Acquisition of positively charged amino acids in HBsAg C-terminus correlates with HBV-induced liver cancer, hampers HBsAg stability and secretion and promotes cell survival Lorenzo Piermatteo Received Received
  SAT-313 Evaluation of predictive factors for postoperative nausea and vomiting in hepatobiliary cancer patients Luciano Beltrão Pereira Received Received
  SAT-314 Immune responses before and after liver transplantation: a cohort study of the induced immune response Dina Leth Mller Received Received
  FRI-314 HCV screening in a tertiary french hospital : just do it Si Nafa Si Ahmed Received Received
  THU-314 PAGE-B and FIB-4 predict the occurence of hepatocellular carcinoma in HBV patients: a french nationwide cohort study GAUTIER BOILLET Received Received
  SAT-315 Andrographolide can potentially rescue unusable liver grafts by reducing fat content, enhancing mitochondrial function, and inhibiting Th1/Th17 immunity Tengfei Si Received Received
  THU-315 High tolerance of hepatitis E virus towards alcohol-based disinfectants Patrick Behrendt Received Received
  THU-316 Multicentre performance evaluation of the Elecsys HCV Duo immunoassay Sam Bunting Received Received
  FRI-316 Maximizing the potential of Cepheid, GeneXpert PCR rapid testing for hepatitis C through use of finger prick blood samples collected into EDTA capillary tubes Anam Choudhry Received Received
  SAT-316 Trends and causes of etiology in adult liver transplant patients: multicenter study Mesut Akarsu Received Received
  THU-317 Intrahepatic transcriptional profiling demonstrates preclinical models of chronic hepatitis B resemble different stages of natural history in humans Ricardo Ramirez Received Received
  SAT-317 A new avatar mouse model to predict the liver immune homeostasis and histologic inflammation of liver transplant patients Soon Kyu Lee Received Received
  FRI-317 Healthcare resource utilization in treatment-nave patients with compensated cirrhosis receiving 8-weeks glecaprevir/pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review Sean Littlewood Received Received
  THU-318 Hepatitis B virus splice variants are associated with reduced likelihood of functional cure and differ across phases of chronic hepatitis B infection Peter Revill Received Received
  SAT-318 Hepatocellular carcinoma and the risk of cancer onset after liver transplantation - role of immune activation and aging profiles Sarah Shalaby Received Received
  SAT-319 The crucial role of PARP poly(ADP-ribose polymerase on the post-ischemic liver injury and inflammation Michitaka Ozaki Received Received
  FRI-319 Screening for hepatitis C in Denmark - the effect of a mobile outreach intervention Sandra Drse Received Received
  THU-319 Understanding acute HCV infection kinetics in humanized mice via an agent-based modeling approach Harel Dahari Received Received
  SAT-320 Mitochondrial transplantation attenuates murine in vivo hepatic ischemia/reperfusion injury Avinash Mukkala Received Received
  THU-320 Presence of sodium taurocholate co-transporting polypeptide and hepatitis B replication markers on placenta: another home for the virus? Ashish Kumar Vyas Received Received
  FRI-320 Screening for HCV infection combined with SARS-CoV-2 vaccination in the Campania region Pietro Torre Received Received
  FRI-321 Treating children with HCV close to home through a virtual national multidisciplinary network Deirdre Kelly Received Received
  THU-321 Exploring dynamic changes in HBcrAg and HBV RNA in e-Antigen negative HBV/HIV patients on antiretroviral therapy: still evidence of integrated activity after 5 years of treatment Ruth Byrne Received Received
  THU-322 Next-generation sequencing of Swiss HEV isolates allows for reconstitution of functional clones Jérme Gouttenoire Received Received
  FRI-322 Association of sustained virologic response with measures of direct-acting antiviral adherence in patients with hepatitis C: data from the ASCEND and ANCHOR investigations Sarah Kattakuzhy Received Received
  FRI-323 ATA haplotype of the interleukin-10 gene and low phase angle are associated with liver cirrhosis in chronic hepatitis C Nataly Lopes Viana Received Received
  FRI-324 Use of Glecaprevir/Pibrentasvir (G/P) for the treatment of HCV infection among fentanyl users: an interim analysis of the GRAND PLAN study Brian Conway Received Received
  THU-324 Combined effect of Vonafexor and Interferon-alpha on HBV replication in primary human hepatocytes David Durantel Received Received
  THU-325 Hepatitis Delta virus quasispecies conservation and variability in ribozyme region Beatriz Pacín Ruiz Received Received
  FRI-325 Indigenous methodologies in practice through community engagement and telehealth outreach increase hepatitis C access to care in Alberta, Canada Sam Lee Received Received
  THU-326 Exosomal cargo as a key player of the immune response after direct-acting antiviral treatment in chronic hepatitis C patients Ioannis-Georgios Koskinas Received Received
  FRI-326 Implication of metabolic associated fatty liver disease and sex differences in the risk of developing liver fibrosis in patients with Hepatitis C Martín Uriel Vázquez Medina Received Received
  FRI-327 Micro-eliminating hepatitis C in a network of 47 English Prisons through an industry, prison healthcare and patient organisation partnership Andy Jones Received Received
  THU-327 Therapeutic suppression of HBV transcripts promotes reappearance of the SMC5/6 complex and cccDNA silencing in vivo without affecting posttranslational modifications of cccDNA-bound histones Lena Allweiss Received Received
  THU-328 Updated national prevalence estimates of chronic hepatitis B virus infection in countries within the European (EU) and European Economic Area (EEA): a systematic review Sandra Bivegete Received Received
  FRI-328 The Viennese epidemic of acute HCV in the era of direct-acting antivirals David JM BAUER Received Received
  FRI-329 Approaches for a hepatitis C-free city: preliminary results Manuel Romero Gomez Received Received
  THU-329 Relevance of HEV detection in ejaculate of chronically infected patients Mathias Schemmerer Received Received
  THU-330 HDV-mediated inhibition of HBV in superinfection mouse model: the role of type I Interferon Beatriz Pacín Ruiz Received Received
  FRI-331 Impact of hepatitis C virus point-of-care (PoC) viral load assay compared to laboratory-based assays on uptake of testing and treatment, and turnaround times: a systematic review and meta-analysis Adam Trickey Received Received
  THU-331 Assessment of Myrcludex or heparin antiviral activity on HBV infection using a 3-dimensional primary human hepatocyte culture system Juliette Besombes Received Received
  FRI-332 Diagnostic accuracy of point-of-care HCV viral load assays for HCV diagnosis: a systermatic review and meta-analysis Weiming Tang Received Received
  THU-332 Concordance of the Xpert hepatitis B viral load test and conventional quantitative PCR in detecting and quantifying viremia using stored plasma and dried blood spot samples in West Africa Gibril Ndow Received Received
  FRI-333 Hepatitis-C virus viral load reflex testing following an innitial positive HCV antibody test: a global systematic review and meta-analysis Weiming Tang Received Received
  THU-333 A high-throughput viral integration sequencing method reveals that mitochondrial DNA is frequently targeted by HBV integration Teresa Pollicino Received Received
  THU-334 Enhanced T cell responses in patients and mouse model of hepatitis B and comorbid non-alcoholic fatty liver disease Nishi Patel Received Received
  FRI-334 Finding cases of hepatitis C for treatment using automated screening in the emergency department is effective, but what is the cost? David Prince Received Received
  FRI-335 A cluster randomized controlled study of secondary distribution of HCV self-test to support micro-elimination in Karachi, Pakistan. Saeed Hamid Received Received
  THU-335 Hepatitis B virus sero-prevalence and genotype distribution among pregnant women in Siem Reap, Cambodia Bunthen E Received Received
  THU-336 Genotype distribution and mutations associated with hepatocellular carcinoma risk among hepatitis B carriers in Goto Islands, Japan Serge Ouoba Received Received
  THU-337 Comprehensive analysis of the different phases of chronic hepatitis B virus infection Michael Basic Received Received
  FRI-337 From extensive to intensive screening, co-operations model of hepatitis C elimination in out-patients and people who inject drug population in southwest of China Qing Lin Received Received
  FRI-338 Using time to positivity of hepatitis rapid detection test results to determine active viremia Saeed Hamid Received Received
  THU-338 Human stem cell-derived hepatic and intestinal culture systems to study HEV transmission along the gut-liver axis Sarah PRALLET Received Received
  THU-339 A novel class of glycan-specific human monoclonal antibodies neutralizing the Hepatitis E Virus Katja Dinkelborg Received Received
  FRI-339 Liver-related mortality among people with hepatitis B and C: a validation study using linked healthcare administrative datasets Syed Hassan Bin Usman Shah Received Received
  THU-340 Increased lymphocyte trafficking and myeloid activation in patients with chronic hepatitis delta Ester García-Pras Received Received
  FRI-340 Identifying risk factors associated with hepatitis C virus infection in participants in the National Health and Nutrition Examination Survey using Super Learner Laura Telep Received Received
  THU-341 Discordant serum HBV DNA and RNA correlation with quantitative HBsAg and high levels of intrahepatic integrated HBV DNA in HBeAg negative chronic hepatitis B Daryl Lau Received Received
  SAT-341 Bulevirtide treatment of hepatitis D in Germany: multicentre real-world experience Katja Deterding Received Received
  SAT-342 Challenges with the cascade of HDV care in Mongolia Nandintsetseg Tsoggerel Received Received
  THU-342 Hepatitis B virus-replicating transgenic mice exhibit a functional but restricted responsiveness to exogenous Tlr3 and Rig-I stimuli Stefan Schefczyk Received Received
  THU-343 Profiling at single hepatocyte level indicates variance in viral replication associated with HBeAg status in chronic hepatitis B patients Marianne Tuefferd Received Received
  SAT-343 Safety, tolerability and pharmacokinetics of single ascending doses of ALG-020572, a GalNAc-conjugated antisense oligonucleotide, in healthy subjects Min Wu Received Received
  FRI-343 Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis Ian Lockart Received Received
  THU-344 Human stem cell-derived hepatocytes as a model for hepatitis D virus infection Huanting Chi Received Received
  FRI-344 Glycomics-based serum marker as reliable tool for assessment of viral response after treatment with direct-acting antiviral drugs in hepatitis C virus infection Nicky Somers Received Received
  SAT-344 Predictors of HBsAg loss after cessation of nucleo(s)tide analogue therapy in asian patients with low HBsAg levels Milan Sonneveld Received Received
  SAT-345 Improvement of liver-stiffness after 6 months of therapy: real-life data for HBV/HDV co-infected patients treated with bulevirtide Alexander Killer Received Received
  THU-345 Hepatitis B viral load variation between the first and third trimesters of pregnancy Stuart Gallacher Received Received
  FRI-345 Post-treatment elevated gamma-glutamyl transferase is the best predictor for future outcomes in HCV patients achieving sustained virological response - data from the german hepatitis C-registry (DHC-R) Stefan Mauss Received Received
  FRI-346 The impact of liver function improvement after direct-acting antiviral therapy on the outcome in hepatitis C virus patients with decompensated cirrhosis Yuki Tahata Received Received
  THU-346 Greater sequence diversity during early hepatitis B virus decline on vebicorvir plus entecavir is associated with a lower level of virus rebound following switch to entecavir monotherapy Kathryn M Kitrinos Received Received
  THU-347 Results from a nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia Maia Tsereteli Received Received
  SAT-347 Model to predict on-treatment restoration of functional HBV-specific CD8 cell response foresees off-treatment HBV control in eAg-negative chronic hepatitis B Julia Peña Asensio Received Received
  FRI-347 De-novo occurrence of portal vein thrombosis in patients with HCV-related cirrhosis after sustained virological response: medium to long term observations from the ongoing PITER cohort Loreta Kondili Received Received
  SAT-348 Antiviral treatment cessation in HBeAg negative chronic hepatitis B: clinical outcome is associated with increase in specific pro-inflammatory cytokines Marte Holmberg Received Received
  THU-348 Clinical impact of drug interaction in the use of antipsychotics by HCV patients treated with pangenotypic direct-acting antivirals Marinela Mendez Received Received
  FRI-348 Suboptimal follow-up, high re-infection, and drug-related death, among HCV-treated people who inject drugs in Tayside, Scotland Christopher Byrne Received Received
  SAT-349 Tenofovir alafenamide for pregnant chinese women with active chronic hepatitis B: a multicenter, prospective, real-world study Qing-Lei Zeng Received Received
  THU-349 Occult hepatitis C infection detection in people who use drugs with or without direct antiviral agents therapy Eliane Silva Received Received
  FRI-349 Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study Joanne Carson Received Received
  THU-350 Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of phase 3 D-LIVR study. Maria Buti Received Received
  FRI-350 Five-years follow-up of cured HCV patients with or without cirrhosis under real-world interferon-free therapy Robert Flisiak Received Received
  SAT-350 Suboptimal virological response to antiviral therapy in chronic hepatitis B as an independent predictor for occurrence of HCC and development of severe liver events Chau-Ting Yeh Received Received
  THU-351 Detection of highly variable RNA-containing viral particles on CNT-based electrochemical impedimetric DNA-nanosensors Victor Hryharovich Received Received
  SAT-351 Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta Dmitry Manuilov Received Received
  SAT-352 Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta Dmitry Manuilov Received Received
  THU-352 Hepatitis B Delta: assesment of knowledge and practices of French non academic hepato-gastroenterologists Jean-Franois Cadranel Received Received
  FRI-352 Reverse Inflamaging: biological age is accelerated in chronic HCV patients and decelerates after HCV cure Carlos Oltmanns Received Received
  THU-353 Hepatitis E seroprevalence in solid organ transplant recipients in Croatia Anna Mrzljak Received Received
  SAT-353 Virologic response to bulevirtide is delayed in cirrhotic HDV patients with clinically significant portal hypertension Mathias Jachs Received Received
  FRI-353 Overall mortality in patients with chronic hepatitis C: major effects of social vulnerability, tobacco smoking, and history of unhealthy alcohol use (ANRS CO22 HEPATHER cohort) Hélène Fontaine Received Received
  SAT-354 Response-guided long-term treatment of chronic hepatitis D patients with bulevirtide - Results of a real world study Mathias Jachs Received Received
  FRI-354 Is routine Ribavirin mandatory for genotype 3 hepatitis C compensated cirrhosis patients receiving Sofosbuvir/Velpatasvir? A meta-analysis Jing Hong Loo Received Received
  THU-354 Microarray analysis of virus-specific IgM and IgG antibodies significantly improves the serological diagnosis of Hepatitis E Virus infection David Springer Received Received
  THU-355 Hepatitis delta virus reflex testing in patients with Hepatitis B improves the HDV screening cascade: 10 years of real-world experience from Avicenne University Hospital, France Segolene Brichler Received Received
  FRI-355 High frequency of hepatitis C virus reinfection following antiviral treatment in the North East of England Sumar Askar Received Received
  SAT-355 HBV RNA levels are associated with virological response to treatment with pegylated interferon alpha in patients with chronic hepatitis D virus infection Lisa Sandmann Received Received
  THU-356 T cell epitope mapping of hepatitis B virus in chronic infection Marie Viuff Received Received
  SAT-356 Management of chronic hepatitis B virus infection within a large integrated health care setting: treatment patterns among kaiser permanente members in southern california, 2008 - 2019 Deborah Malden Received Received
  SAT-357 Dose-dependent durability of hepatitis B surface antigen reductions following administration of a single dose of VIR-3434, a novel neutralizing vaccinal monoclonal antibody Kosh Agarwal Received Received
  FRI-357 Direct acting antiviral agents improve survival in patients with hepatitis C virus related hepatocellular carcinoma Hyun Young Woo Received Received
  THU-357 The Comparison of Tenofovir Alafenamide Fumarate with Tenofovir Disoproxil Fumarate in Preventing Hepatitis B Transmission in Mothers with High Viral Load: A Retrospective Cohort Study Yunxia Zhu Received Received
  SAT-358 Quantification of HBV hepatocyte burden using novel multiplex immunofluorescence staining and image analysis reveals substantial reduction in HBV liver burden with anti-viral treatment Abhishek Aggarwal Received Received
  FRI-358 Lack of Alpha-fetoprotein reduction after successful Hepatitis C treatment in patients with cirrhosis predicts the development of hepatocellular carcinoma during surveillance - a single unit real-world experience Aoife Alvain Received Received
  THU-358 Detection of notable hepatitis B virus serologic activity after hepatitis B surface antigen seroclearance Danny Wong Received Received
  THU-359 Comparison of on-treatment ALT or FIB-4 as an on-treatment biomarker of hepatitis B treatment for liver cirrhosis patients JOO HYUN OH Received Received
  SAT-359 GST-HG141 inhibits de novo HBV cccDNA formation in cultured primary human hepatocytes Vadim Bichko Received Received
  FRI-360 The long-term effect of Hepatitis C eradication by direct-acting antivirals on patients mood and quality of life as determined by the Becks Depression Inventory and EQ5D Quality of Life questionnaires - a single unit study Aoife Alvain Received Received
  SAT-360 Predictive factors of virological response at one year in patients with chronic HBV/HDV co-infected treated with Bulevirtide Victor de Lédinghen Received Received
  THU-360 Liver fibrosis burden determines risk of hepatocellular carcinoma among patients with hepatitis B surface antigen seroclearance Lung-Yi Mak Received Received
  FRI-361 Assessing sustained virological response and reinfection from dried blood spots within an on-site hepatitis C diagnosis and treatment model of care in a harm reduction centre Sabela Lens Received Received
  THU-361 Estimating the prevalence of hepatitis delta infection among foreign-born adults with chronic hepatitis B in the United States Robert Wong Received Received
  SAT-361 Impact of baseline viral load on hepatocellular carcinoma risk during antiviral treatment in non-cirrhotic patients with HBeAg-positive chronic hepatitis B Won-Mook Choi Received Received
  THU-362 Secular trend of the accuracy of hepatocellular carcinoma risk scores in treated chronic hepatitis B patients in 2005-2020: a territory-wide study of 48,706 subjects Terry Cheuk-Fung Yip Received Received
  SAT-362 Therapeutic vaccination with CLB-3000 in a mouse model of chronic hepatitis B induces anti-HBs responses associated with functional cure Aileen Rubio Received Received
  FRI-363 Lack of fibrosis remodelling in chronic hepatitis C post SVR, as demostrated by YKL-40, is predictive of hepatocellular carcinoma ocurrence Maria Fernanda Guerra Veloz Received Received
  THU-363 Risk prediction of hepatocellular carcinoma in chronic hepatitis B patients outside current treatment criteria Gi-Ae Kim Received Received
  SAT-363 Evaluation of the disposition and mass balance recovery of vebicorvir, a first generation hepatitis B core inhibitor, in rats and humans Rob Coover Received Received
  FRI-364 HCV reinfection associated with IDU and cocaine use in a cohort of people with OUD: 4 Year follow-up data from the ANCHOR cohort Elana Rosenthal Received Received
  SAT-364 Effect of tenofovir disoproxil fumarate treatment on intrahepatic viral burden and liver immune microenvironment in chronic hepatitis B patients with minimally elevated serum alanine aminotransferase Abhishek Aggarwal Received Received
  THU-364 Suboptimal glycemic control is associated with adverse clinical outcomes in patients with chronic hepatitis B and diabetes mellitus Lung-Yi Mak Received Received
  FRI-365 Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: a multicenter study Yu Rim Lee Received Received
  SAT-365 Safety, pharmacokinetics, and antiviral activity of the class II capsid assembly modulator ALG-000184 in subjects with chronic hepatitis B Benedetta Massetto Received Received
  THU-365 Statin use and surface antigen loss in patients with chronic hepatitis B Shahed Iqbal Received Received
  THU-366 Patient engagement in hepatitis B clinical trials: HBV cure is a motivation for participation in all ethnically diverse patients Almuthana Mohamed Received Received
  SAT-366 Deeper virologic suppression with the addition of vebicorvir, a first-generation hepatitis B core inhibitor, to entecavir correlates with reduced inflammation and fibrosis-4 index in treatment nave patients with HBeAg positive chronic hepatitis B Gregory Suess Received Received
  THU-367 Anti-HDV reflex testing increases the number of hepatitis D cases diagnosed in both academic and community centers Adriana Palom Received Received
  SAT-367 Safety, tolerability, pharmacokinetics, and preliminary antiviral activity of the capsid assembly modulator (CAM) ZM-H1505R after multiple escalatiing oral dosed in patients with chronic hepatitis B virus (CHB) Infection Jiajia Mai Received Received
  FRI-367 Direct-acting antiviral treatment in Albanian patients with chronic hepatitis C and advanced liver fibrosis Liri Cuko Received Received
  THU-368 HBVoice: a framework to enhance advocacy for patients and communities affected by hepatitis B virus infection Philippa Matthews Received Received
  FRI-368 Improved recurrence-free survival rates in patients with HCV-related hepatocellular carcinoma and sustained virological response to direct-acting antivirals Anca Trifan Received Received
  SAT-368 Evaluation of renal and bone safety at 4 years in post-liver transplant patients with chronic kidney disease receiving Tenofovir Alafenamide for HBV prophylaxis Edward Gane Received Received
  SAT-369 Functional cure based on pegylated interferon alpha therapy in nucleoside analog-suppressed HBeAg negative chronic hepatitis B: a multicenter real-world study (Everest Project in China) - 3.5 years data update Chan Xie Received Received
  THU-369 HBeAg-positive patients with HBsAg135IU/mL or HBcrAg3.6logU/mL have more chance to be HBsAg loss after nucleos(t)ide analogue cessation Yandi Xie Received Received
  FRI-369 Long-term outcomes associated with task-shifting of HCV treatment by non-specialist providers: five year follow-up from the ASCEND cohort Sarah Kattakuzhy Received Received
  SAT-370 Understanding the dynamics of HBsAg decline through model-informed drug development (MIDD) of JNJ-3989 and JNJ-6379 for the treatment of chronic hepatitis B virus infection (CHB) Huybrecht Tjollyn Received Received
  THU-370 Serum markers of cccDNA transcriptional activity (HBcrAg and pre-genomic HBV RNA) and large HBsAg (LHBs) protein are predicting response to pegylated interferon in HDV infection Ivana Carey Received Received
  FRI-371 Distinct hepatocellular carcinoma risks in treated chronic hepatitis C patients with different definitions of advanced chronic liver disease Yen-Chun Liu Received Received
  SAT-371 Serum HBsAg and ddPCR HBV-DNA as predictive parameters of HBsAg loss after nucleo(s)tide analogue (NA) treatment discontinuation in non-cirrhotic patients with chronic hepatitis B Anna Francesca Guerra Received Received
  THU-371 A decision-making model for prediction of a stable disease course in chronic hepatitis B patients Imri Ofri Received Received
  FRI-372 Hepatocellular carcinoma risks of liver fibrosis changes after viral eradication in chronic hepatitis C patients Yen-Chun Liu Received Received
  THU-372 Healthcare resource utilization and costs of hepatitis delta in the United States: an analysis of all-payer claims database Ankita Kaushik Received Received
  SAT-372 Exploring hepatitis B virus as an immunotherapeutic target for clinical trials of adoptively transferred T cells Spyridoula Vasileiou Received Received
  FRI-373 Change in fibrosis and clinical progression three years after sustained virological response induced by direct antiviral agents in HIV/HCV subjects Maria Carnevali Frias Received Received
  SAT-373 Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings Victor de Lédinghen Received Received
  THU-373 Validation of an internal hepatitis D virus DNA quantitative assay: developing assay suitable for global clinical application and clinical trials assessment Natalie Bolton Received Received
  THU-374 Early increase in HBcrAg levels after peginterferon withdrawal predicts subsequent ALT flares Sylvia Brakenhoff Received Received
  SAT-374 Two-year safety and efficacy of tenofovir alafenamide in chronic hepatitis B: a HEllenic multicenter ReAl-life CLInical Study (HERACLIS-TAF) George Papatheodoridis Received Received
  FRI-374 FOCUS Project: preliminary results toward hepatitis C Virus screening and elimination in Almería, Spain Marta Casado Received Received
  THU-375 Hepatitis B pre-genomic RNA differentiates HBeAg-negative disease from infection: time to refine disease stages with new biomarkers? Bo Wang Received Received
  SAT-375 Treatment of chronic hepatitis B in sub-saharan Africa: 5-year results of a pilot program in Ethiopia Asgeir Johannessen Received Received
  THU-376 Evaluating hepatitis delta virus disease prevalence and patient characteristics among adults in the United States: an analysis of all-payer claims database Ankita Kaushik Received Received
  SAT-376 Decrease in the burden of integrated hepatitis B virus DNA in chronic hepatitis B patients with minimally elevated alanine aminotransferase on tenofovir disoproxil fumarate as revealed by long-read DNA-sequencing David Pan Received Received
  FRI-376 Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC Eleonora Alimenti Received Received
  SAT-377 Serum HBV RNA levels are associated with risk of hepatitis flare after stopping NA therapy in HBeAg-negative patients Alexander Thompson Received Received
  FRI-377 A 4 Year Multi-Centre Study of Persons Who Inject Drugs in Luxembourg, looking at Hepatitis C Virus Seroprevalence, Treatment Uptake and Reinfection Rates Madiha Sharaf Received Received
  THU-377 Hepatitis delta in Northern Portugal - a long-term follow-up study Isabel Garrido Received Received
  SAT-378 Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naive patients with chronic hepatitis B Jihye Lim Received Received
  THU-378 Impact of hepatitis B virus infection on liver-related death among people tested for HBV in British Columbia: results from a large longitudinal population-based cohort study Makuza Jean Damascene Received Received
  SAT-379 Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study Alessandro Loglio Received Received
  THU-380 Evidence of extensive transcriptionally active HBV integrations involving genetic regions crucial for cell proliferation in the setting of HBeAg positive infection Romina Salpini Received Received
  SAT-380 The orally available sodium/taurocholate co-transporting polypeptide inhibitor A2342 blocks hepatitus B and D entry in vitro Paris Fossa Received Received
  THU-381 In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy Stefano DAnna Received Received
  FRI-381 Benefits associated with HCV cure in people with mental disorders Elias Benabadji Received Received
  SAT-381 Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients Sara Colonia Uceda Renteria Received Received
  FRI-382 Dismal prognosis for cirrhotic HCV patients after initial DAA treatment failure, rescue therapy may be life-saving Johan Westin Received Received
  THU-382 Absence of hepatitis B virus (HBV) in at-risk infants receiving early antiretroviral therapy in a cohort of HIV-transmitting mothers in KwaZulu-Natal, South Africa Anna McNaughton Received Received
  THU-383 Rising clinical and economic burden among hepatitis D patients who attended Spanish hospitals Maria Buti Received Received
  SAT-383 ABI-4334, a novel inhibitor of hepatitis B virus core protein, promotes formation of empty capsids and prevents covalently closed circular DNA formation by disruption of incoming capsids Gregory Suess Received Received
  FRI-383 Requests for drug-drug interaction data on direct-acting antivirals and enzyme inducing anti-epileptic agents: an overview of the HEP Interaction checker database of the University of Liverpool David Burger Received Received
  THU-384 Analysis from national hospital discharge records database in Spain : increased baseline comorbidity burden including liver severity among HDV coinfection versus HBV monoinfection patients Maria Buti Received Received
  SAT-384 Real-word high adherence to hepatitis B antiviral treatment practice guidelines in Israel Yana Davidov Received Received
  FRI-384 Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset Olivia Burgess Received Received
  SAT-385 No detectable resistance to bulevirtide in participants with chronic hepatitis D (CHD) through 24 weeks of treatment Julius Hollnberger Received Received
  THU-385 Value of intrahepatic HBV markers in virologically suppressed HBV and HDV infected patients Ester García-Pras Received Received
  FRI-385 Sofosbuvir plus velpatisvir for 8 weeks in patients with acute hepatitis C: multicenter, single arm, phase 2 study (The HepNet acute HCV-V study) Julia Kahlhfer Received Received
  THU-386 Hepatitis Delta virus infection in patients with chronic hepatitis B is associated with greater risk of liver disease progression and liver-related mortality: a systematic review and meta-analysis Robert G. Gish Received Received
  FRI-386 Full-length genome characterization of inherently resistant african HCV genotype 1, subtype 1l in patients failing DAA-based therapy Erwan Vo Quang Received Received
  SAT-386 The HBV siRNA, ALG-125755, demonstrates a favourable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model Megan Fitzgerald Received Received
  SAT-387 Hepatitis delta management in the United Status: an analysis of all-payer claims database Ankita Kaushik Received Received
  FRI-387 Treating HCV in dual diagnosis acute psychiatric inpatients with substance use disorder vera dreizin Received Received
  THU-387 The serum markers of cccDNA transcriptional activity have a role in predicting long-term outcomes in children with perinatally acquired HBV infection Christiana Moigboi Received Received
  FRI-388 Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study Laura Whiteley Received Received
  THU-388 Presence of liver inflammation and fibrosis in Asian patients with chronic hepatitis B in the grey zone Jiacheng Liu Received Received
  SAT-388 Evaluation of the drug-drug interaction profile of vebicorvir, a first-generation hepatitis B core inhibitor: findings from phase 1 and phase 2a studies Gregory Suess Received Received
  SAT-389 Improving the pharmacokinetic profile of the hepatitis B virus core inhibitor ABI-H3733 following oral administration: results from new formulation activities Gregory Suess Received Received
  THU-389 Characteristics and renal function in patients with chronic hepatitis B virus infection: baseline data from the phase 2b B-Clear study Seng-Gee Lim Received Received
  FRI-389 HCV-RNA viral load fingerstick assay as a simplified strategy for screening and linkage to care of people who use drugs attending 3 french addiction centers Denis Ouzan Received Received
  THU-390 Characterisation of baseline complement values in patients with chronic hepatitis B virus infection in the phase IIb B-clear study Jennifer Cremer Received Received
  FRI-390 Pangenotypic and genotype-specific antivirals in the treatment of genotype 4 infected patients with HIV coinfection Dorota Zarebska-Michaluk Received Received
  SAT-390 EDP-514, a novel pangenotypic class II hepatitis B virus core inhibitor: final results of a 28-day phase 1b study in nuc-suppressed chronic hepatitis B patients Jordan Feld Received Received
  THU-391 Estimations of the global prevalence and clinical burden of occult hepatitis B infection (OBI): a systematic review and meta-analysis Yu Ri Im Received Received
  SAT-391 Preclinical activity of small-molecule oral PD-L1 checkpoint inhibitors capable of reinvigorating T cell responses from chronic hepatitis B patients Emily P. Thi Received Received
  FRI-391 Long-term follow-up of HCV resistance-associated substitutions after DAA treatment failure Julia Dietz Received Received
  FRI-392 Real-life effectiveness and safety of sofosbuvir/velpatasvir in difficult to treat hepatitis C patients Hyun Young Woo Received Received
  THU-392 Time for universal screening for hepatitis D? A study describing screening patterns, characteristics and outcomes of hepatitis D virus infection Rohit Nathani Received Received
  SAT-392 Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects (HS) and subjects with chronic hepatitis B (CHB) Edward Gane Received Received
  THU-393 Distribution of patients by guideline-defined disease phase and/or grey zones in B-Clear, an international multicentre clinical trial Seng-Gee Lim Received Received
  SAT-393 EDP-514, a potent pangenotypic class II hepatitis B virus core inhibitor, demonstrates significant HBV DNA and HBV RNA reductions in a phase 1b study in viremic, chronic hepatitis B patients Man-Fung Yuen Received Received
  FRI-393 Polypharmacy and prevalence of multi drug-drug interactions in hepatitis C patients treated with pangenotypic direct acting antivirals: an analysis from three european countries Alessandra Mangia Received Received
  THU-394 Benign course of HBV reactivations during DAAs in untreated ENI with HBV-HCV co-infections correlates with different HBsAg kinetics compared to NAs treated CHB patients Piero Colombatto Received Received
  FRI-394 Use of comedication in patients with hepatitis C and addiction or drug abuse treated with direc-acting antivirals: implication in drug-drug interactions Marinela Mendez Received Received
  SAT-394 Increased HBsAg reduction and relapse outcomes in HBeAg negative patients with chronic hepatitis B after nucleos(t)ide analogue withdrawal: 4.5 year follow up of the Toronto STOP Study Arif Sarowar Received Received
  FRI-395 Five years of progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-October 2021 Tengiz Tsertsvadze Received Received
  THU-395 Predictors of advanced liver fibrosis in chronic hepatitis B patients in the daily clinical practice Fadi Abu Baker Received Received
  SAT-395 Pharmacodynamics of durable HBsAg suppression by AB-729 short interfering RNA correlates with pharmacokinetics of RNA-induced silencing complex (RISC) loading within liver Emily P. Thi Received Received
  SAT-396 Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA chronic hepatitis B patients Sharie C Ganchua Received Received
  FRI-396 Simplifying mathematical-based response guided therapy for reducing duration of direct acting antivirals in chronic hepatitis C infected patients Harel Dahari Received Received
  THU-396 Metabolic associated fatty liver disease is associated with appendicular lean soft tissue abnormalities in patients with chronic hepatitis B Luciana Diniz Silva Received Received
  THU-397 The course of COVID-19 infection in patients with chronic hepatitis B and Delta onur keskin Received Received
  FRI-397 Epidemiology of hepatitis B virus infection among hepatitis C (HCV) infected patients treated within HCV elimination program in Georgia Senad Handanagic Received Received
  SAT-397 Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells Emily P. Thi Received Received
  THU-398 Serum soluble program cell death-1 is predictive of hepatocellular carcinoma in untreated chronic hepatitis B patients Rachel Wen-Juei Jeng Received Received
  SAT-398 Characterizing of hepatitis B virus serum RNA kinetics during TDF plus pegylated interferon alfa-2a with and without nucleic acid polymers Harel Dahari Received Received
  FRI-398 Direct-acting antivirals and the risk of hepatitis B reactivation in hepatitis B and C coinfected patients: a systematic review and meta-analysis JOO HYUN OH Received Received
  FRI-399 Inhibition of high fitness viruses by different antiviral strategies when the infection has started Carlos García-Crespo Received Received
  THU-399 Parameters related to ALT elevation in patients with HBeAg negative chronic infection Fulya Gunsar Received Received
  SAT-399 Early antiviral efficacy of tenofovir alafenamide fumarate in the initial treatment of chronic hepatitis B patients with normal ALT Xin Chi Received Received
  FRI-400 Treatment of hepatitis C in primary healthcare in the country of Georgia Tengiz Tsertsvadze Received Received
  THU-400 Clinical evidence for unconventional hepatitis delta virus infections in endemic countries Mary Rodgers Received Received
  SAT-400 Viral and ALT kinetics after nucleos(t)ide analogue withdrawal among patients who remain off-therapy: results from a global, multi-ethnic cohort of chronic hepatitis B patients (RETRACT-B study) Grishma Hirode Received Received
  FRI-401 Optimal screening and linkage to care model to achieve hepatitis C elimination targets in Georgia Tengiz Tsertsvadze Received Received
  SAT-401 Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B Francois Gonzalvez Received Received
  THU-401 Rapid point-of-care test for hepatitis B core-related antigen (HBcrAg) to identify HBV-infected patients eligible for antiviral therapy Yusuke Shimakawa Received Received
  SAT-402 Incorporation of novel ASO chemistries significantly improves the potency and durability of HBV ASOs in the AAV-HBV mouse model Jin Hong Received Received
  FRI-402 Establishing a protocol for management and DAA treatment of HCV during pregnancy: adherence to a co-located care protocol Tatyana Kushner Received Received
  THU-402 Prevalence of HBV infection and receiving antiviral treatment for eligible patients in blood relatives from clustering families of HBV infection with unfavorable prognoses and cascading of care linked to treatment in West China yuan yang Received Received
  THU-403 Liver inflammation in asian chronic hepatitis B patients with detectable HBV-DNA and normal alanine aminotransferase according to diverse upper limits of normal Rui Huang Received Received
  FRI-403 Sofosbuvir/Velpatasvir (S/V) for the treatment of HCV infection among vulnerable inner-city residents: extending the results of clinical trial Brian Conway Received Received
  FRI-404 High efficacy and safety of pan-genotypic direct-acting antiviral regimens in adolescents and children: a global systematic review to inform new World Health Organization recommendations Giuseppe Indolfi Received Received
  THU-404 Diversity of circulating HBV genomes and impact on viral infection Jules Sotty Received Received
  FRI-405 Early vs. late treatment for hepatitis C virus discordant solid organ transplantation and direct acting antivirals: a meta-analysis Madison Gunn Received Received
  THU-405 Chronic hepatitis delta with normal ALT and hepatitis D viremia Cihan Yurdaydin Received Received
  SAT-405 Evaluation of quantitative HBsAg levels in chronic hepatitis B - a targeted literature review Vera Gielen Received Received
  SAT-406 Nucleoside/nucleotide analogoues monotherapy is safe and efficient for the prevention of HBV flare-ups after liver transplantion in the long term orly sneh arbib Received Received
  THU-406 Hepatitis B core related antigen, not as good as it seems: a critique and systematic review Yong Chuan Tan Received Received
  FRI-406 Effectiveness of pangenotypic retreatment of HCV infection after prior failure of pangenotypic therapies Robert Flisiak Received Received
  THU-407 Utilizing phenotyping algorithms as tools for increasing linkage to guideline-concordant care in patients at risk for hepatitis B Brooke Wyatt Received Received
  FRI-407 Infrequent Hepatitis C genotypes/subtypes in patients treated with DAA-based regimens: successes and failures Isaac Ruiz Received Received
  SAT-407 A new method to identify co-variation in hepatitis B virus whole genome sequences identifies networks of polymorphisms associated with drug resistance Philippa Matthews Received Received
  SAT-408 Baseline bile acid levels but not bile acid increases during bulevirtide treatment of hepatitis D are associated with HDV RNA decline Katja Deterding Received Received
  FRI-408 Preemptive treatment with glecaprevir and pibrentasvir prevents HCV transmission from HCV viraemic donors to solid organ transplant recipients (single centre experience) So&328;a Fra&328;ková Received Received
  THU-408 Hepatitis B virus antigen reduction effect of RO7049389 plus NUC with/without Peg-IFN in chronic hepatitis B patients Jinlin HOU Received Received
  SAT-409 Low levels of qHBsAg and tenofovir therapy are associated with successful treatment withdrawal in HBeAg negative chronic hepatitis B: results from spanish multicentric study Anna Pocurull Received Received
  THU-409 Presence of HbeAg, HBV DNA in cord blood and down regulation of TLR9 may act as predictive marker for HBV Mother to child transmission Simanta Kalita Received Received
  FRI-409 Hepatitis C care cascade challenges in the homeless population. A case by case model of delivering care Maria Fernanda Guerra Veloz Received Received
  SAT-410 Preliminary results of the effectiveness and safety of Tenofovir Alefenamide Fumarate prophylaxis in HBV-infected individuals, who received chemo/immunosuppressive therapy FEYZA GUNDUZ Received Received
  THU-410 Patients with CHD coinfection have greater comorbidities, higher healthcare resource use and costs than CHB monoinfection - results from a Spanish national hospital database Maria Buti Received Received
  FRI-410 Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment nave patients with compensated cirrhosis: real-world experience from Taiwan HCV Registry Chao-Hung Hung Received Received
  THU-411 Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial Ohad Etzion Received Received
  FRI-411 Reported safety of HCV direct-acting antivirals with opioids: 2017 to 2021 Anthony Martinez Received Received
  SAT-411 Real life efficacy, renal and lipid profile data of tenofovir alafenamide in switched chronic hepatitis B patients Omer Fehmi Tabak Received Received
  THU-412 Establishment of a new diagnostic model for significant liver tissue damage in patients with chronic hepatitis B virus infection in the immune tolerance phase Airong Hu Received Received
  SAT-412 Mathematical modeling of HDV RNA kinetics suggests high peginterferon Lambda efficacy in blocking viral production: insights from the LIMT-1 study Harel Dahari Received Received
  SAT-413 Heterologous prime-boost immunotherapy circumvents tolerance and induces broadly neutralizing antibodies that protects against hepatitis B and D co-infection and hepatitis D super-infection Lars Frelin Received Received
  THU-413 Provider factors shaping Hepatitis Delta Screening Dewan Giri Received Received
  FRI-414 Impact of the presence of the infectious disease specialist in Addiction Services (SerDs) as a Point-of-Care to meet WHO goal of HCV eradication Chiara Fanelli Received Received
  SAT-414 Real-world data on treatment with bulevirtide in patients with chronic hepatitis B and D coinfection Toni Herta Received Received
  THU-414 Changes of enhanced liver fibrosis score predict hepatocellular carcinoma in chronic hepatitis B patients receiving antiviral treatment Yan Liang Received Received
  FRI-415 Eliminating hepatitis C virus infection in prisons: 7 years of experience Frederico Miguel Duarte Received Received
  SAT-415 Higher rates of virological relapse after nucleos(t)ide analogue withdrawal in HBeAg-negative versus positive chronic hepatitis B patients: results from a global, multi-ethnic cohort of patients with chronic hepatitis B (RETRACT-B Study) Grishma Hirode Received Received
  THU-415 Trends in decompensated cirrhosis and hepatocellular carcinoma diagnosis among people with a hepatitis B notification in New South Wales: a population-based data linkage study Syed Hassan Bin Usman Shah Received Received
  FRI-416 Real-World Value and Innovation of Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C at Kaiser Permanente Southern California Alon Yehoshua Received Received
  THU-416 Point of care screening tests for hepatitis B and commitment of a dedicated nurse lead to succesful linkage to care of ethnic minorities Axelle Vanderlinden Received Received
  SAT-416 Real life efficacy and tolerability of Tenofovir alafenamde fumarate in liver transplant recipients: a multicenter study Suna Yapali Received Received
  SAT-417 Impact of patient-related factors on the pharmacokinetics of Bulevirtide Renu Singh Received Received
  THU-417 Prediction of comprehensive prognosis through computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B Heejin Cho Received Received
  THU-418 Analysis on the normal threshold of alanine aminotransferase level based on liver pathology in patients with chronic hepatitis B Airong Hu Received Received
  SAT-418 Reduction of liver stiffness in chronic hepatitis B patients treated with tenofovir disoproxil fumarate: a prospective observational study Heejin Cho Received Received
  FRI-418 Treatment options for hepatitis C in pregnancy: A systematic review of the evidence and future research needs Lindsey Hiebert Received Received
  SAT-419 Toll-like receptor 8 agonism activates monocytes and induces antiviral cytokine production by T-cells in HIV and chronic hepatitis B coinfection Lydia Tang Received Received
  THU-419 Prevalence rates and eligibility for antiviral treatment against hepatitis B in Casamance, Senegal Vic Arendt Received Received
  THU-420 Comorbidities, and not viral load, are predictors of cirrhosis in AgHBe-negative chronic infection Sara Archer Received Received
  SAT-420 Comparison of body weight and lipid profiles following tenofovir disoproxil fumarate or entecavir switching to tenofovir alafenamide - an interim analysis Pin-Nan Cheng Received Received
  SAT-421 Real life efficacy and tolerability of Tenofovir Alafenamide Fumarate in patients with hepatitis-B virus-related cirrhosis Suna Yapali Received Received
  THU-421 A systematic literature review and meta-analysis of primary sources reporting health state preference values in chronic hepatitis B, C, and D Sarah Hofmann Received Received
  SAT-422 Effects of the siRNA JNJ-3989 and/or the capsid assembly modulator (CAM-N) JNJ-6379 on viral markers of chronic hepatitis B (CHB): Results from the REEF-1 study Man Fung Yuen Received Received
  THU-422 Hepatitis B transmission in early life in very remote Aboriginal communities in northern Australia Jane Davies Received Received
  THU-423 the changing scenario of HBV chronic related disease in the transplant setting sara battistella Received Received
  SAT-423 Safety, pharmacokinetics and antiviral activity of GST-HG141, a hepatitis B virus capsid assembly modulator, in subjects with chronic hepatitis B Vadim Bichko Received Received
  SAT-425 Randomized, double-blind, placebo-controlled trial of Tenofovir Alafenamide in children and adolescents with Chronic Hepatitis B Kathleen Schwarz Received Received
  SAT-426 The discovery of AMS-I-1274, a high potent and orally active capsid-assembly modulator against hepatitis B virus Jung-Hee Kim Received Received
  SAT-427 Viral nucleic acids suppression activity of RO7049389 plus NUC with/without Peg-IFN in virologically-suppressed and naive chronic hepatitis B patients: 48-week treatment and post-treatment follow up Man-Fung Yuen Received Received
  SAT-428 Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) combined with low-dose nivolumab (LDN) in virally-suppressed patients with CHB on nucleos(t)ide analogues Eleanor Barnes Received Received
  SAT-429 Bulevirtide monotherapy for 48 weeks in HDV patients with compensated cirrhosis and clinically significant portal hypertension Elisabetta Degasperi Received Received
  SAT-430 Bulevirtide avoids future clinical events and related costs compared to pegylated-interferon alpha in chronic hepatitis D in Spain Raquel Domínguez-Hernández Received Received
  THU-431 Outcomes of pregnancy in patients with autoimmune hepatitis in the Netherlands Susan Fischer Received Received
  SAT-431 Quantitative HBsAg(qHBsAg) as an endpoint to stop nucleos(t)ide analogues in Chronic Hepatitis B: A meta-analysis with meta-regression Seng Gee Lim Received Received
  THU-432 Cholangiopathy after severe COVID-19: what do we know so far? Valéria Ferreira de Almeida e Borges Received Received
  SAT-432 Low level of HBcrAg is beneficial to functional cure obtained with pegylated interferon therapy in inactive HBsAg carriers Zhenhuan Cao Received Received
  THU-433 Enhanced liver fibrosis score correlates with transient elastography in patients with treated autoimmune hepatitis Anna Stoelinga Received Received
  SAT-433 Comparative risk of hepatocellular carcinoma in patients with chronic hepatitis B receiving tenofovir- or entecavir-based regimens: a meta-analysis using individual patient data Isabel Haber Received Received
  SAT-434 VIR-2218 plus VIR-3434 combination therapy reduces hepatitis B virus surface antigen levels in vivo Julia Noack Received Received
  THU-434 Rationale for evaluation of PLN-74809 treatment in participants with primary sclerosing cholangitis in Phase 2a study INTEGRIS-PSC Éric Lefebvre Received Received
  THU-435 Acute hepatitis after COVID-19 vaccine: case series by the International autoimmune hepatitis group (IAIHG) and the european reference network on hepatological diseases (ERN RARE-LIVER) Benedetta Terziroli Beretta-Piccoli Received Received
  SAT-435 Safety, pharmacokinetics, and antiviral activity of the S-antigen Transport Inhibiting Oligonucleotide Polymers (STOPS) drug candidate ALG-010133 in subjects with chronic hepatitis B Edward J Gane Received Received
  SAT-436 Costimulation of CD40 and type-I interferon immune pathways by a bifunctional molecule in HBV infection models and healthy non-human primates Xavier Marniquet Received Received
  THU-436 Scheduled endoscopic program for patients with primary sclerosing cholangitis improves transplant-free survival and enables early risk stratification Burcin zdirik Received Received
  SAT-437 IMC-I109V, a novel T cell receptor (TCR) bispecific (ENVxCD3) designed to eliminate HBV-infected hepatocytes in chronic HBV patients: initial data from a first-in-human study Lucy Dorrell Received Received
  THU-437 Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study Kristin Kaasen Jrgensen Received Received
  SAT-438 Long-term outcomes after cessation of antiviral therapy in HBeAg negative patients Rachel Wen-Juei Jeng Received Received
  THU-438 Analyses of obeticholic acid treatment retention in UK patients based on medicine delivery data Carl Gibbons Received Received
  SAT-439 Bepirovirsen, antisense oligonucleotide (ASO) against hepatitis B virus (HBV), harbors intrinsic immunostimulatory activity via Toll-like receptor 8 (TLR8) preclinically, correlating with clinical efficacy from the Phase 2a study Shihyun You Received Received
  THU-439 Real-world prevalence of pruritus with obeticholic acid: a systematic literature review and meta-analysis Leighland Feinman Received Received
  SAT-440 Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting Harel Dahari Received Received
  THU-440 Cognitive symptoms in non-cirrhotic primary biliary cholangitis Naw April Phaw Received Received
  THU-441 Screening and surveillance of biliary neoplasia based on brush cytology in primary sclerosing cholangitis (PSC): prevalence and outcomes Martti Frkkil Received Received
  SAT-441 Mechanistic Pharmacokinetics/Pharmacodynamics modelling of the simultaneous effects of bepirovirsen on Hepatitis B surface antigen and alanine transaminase changes in Chronic Hepatitis B patients: Phase 2b analysis to inform Phase 3 decision-making Ahmed Nader Received Received
  THU-442 Impact of pruritus in primary sclerosing cholangitis (PSC): a multinational survey Kris Kowdley Received Received
  SAT-442 Improved treatment response and bone density in patients with chronic hepatitis B (CHB) switched to tenofovir alafenamide (TAF) from other nucleos(t)ide analogue: 96-week results from a prospective multinational study Eiichi Ogawa Received Received
  THU-443 A dynamic approach to modelling baseline disease status and ALT elevation over follow-up on clinical-event free survival in autoimmune hepatitis: a canadian multicentre cohort Christina Plagiannakos Received Received
  SAT-443 Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg subjects Timothy Eley Received Received
  SAT-444 Identification of novel antivirals against Hepatitis Delta Virus infection via High Throughput Screening Eirini Tseligka Received Received
  THU-444 Secondary sclerosing cholangitis following COVID-19 disease: a multicenter retrospective study Marcus Maximilian Mcke Received Received
  SAT-445 Generation and functional analsis of spacer modified HBV-specific chimeric antigen receptors that harbor a Fab fragment as binding domain Zhe Xie Received Received
  THU-445 The efficacy of combined treatment of bezafibrate and ursodeoxycholic acid was reduced in patients with primari cholangitis at advanced stage Kosuke Matsumoto Received Received
  SAT-446 Randomised double-blind study of nitazoxanide for virologically suppressed HBeAg negative Chronic Hepatitis B Yong Chuan Tan Received Received
  THU-446 Extrahepatic autoimmune diseases in autoimmune hepatitis: effect on mortality Rasmine Birn-Rydder Received Received
  SAT-447 Low-level viremia in patients with chronic hepatitis B receiving entecavir, tenofovir and tenofovir alafenamide xiaohao Wang Received Received
  THU-447 Confidence in treatment is contributing to quality of life in patients with autoimmune liver diseases. The results of ERN-RARE Liver online survey Ewa Wunsch Received Received
  SAT-448 Continued suppression of viral markers observed following discontinuation of nucleos(t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729 Man-Fung Yuen Received Received
  THU-448 A pilot study of PBC symptom management with melatonin and fenofibrate: the PIMBLE study Amanda Nicoll Received Received
  THU-449 Portal hypertension-associated clinical features in patients with primary biliary cholangitis are of distinct prognostic value Lukas Burghart Received Received
  SAT-449 Tenofovir alafenamide fumarate increased lipid levels in hepatitis B virus patients Wenjuan Zhao Received Received
  THU-450 The low incidence of HBV reactivation among anti-HBc subjects on immunotherapy reduces the impact of suboptimal screening rate Laia Aceituno Received Received
  SAT-450 Off-therapy cure of Hepatitis Delta after 3 years of Bulevirtide monotherapy in a patient with compensated advanced cirrhosis Maria Paola Anolli Received Received
  THU-451 The ABCB4 variant c.711 increases liver injury in PBC but not in PSC: prospective analysis with a median follow-up of 7 years in 331 patients Marcin Krawczyk Received Received
  SAT-451 Combination treatment of a PAPD5/7 inhibitor with an antisense oligonucleotide bepirovirsen with concurrent dosing shows additive HBsAg decreases in the AAV-HBV mouse model Martin Leivers Received Received
  FRI-451 Over-responsiveness of the IL-6/STAT3 pathway in inflammatory CD4 T cells of patients with primary sclerosing cholangitis Leona Dold Received Received
  FRI-452 Dosing ileal bile acid transporter inhibitors in the fasted state minimizes gastrointestinal adverse effects while maintaining pharmacodynamic effect Cory Kostrub Received Received
  SAT-452 Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection not on stable nucleos(t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study Seng Gee Lim Received Received
  THU-452 A multicentric study to estimate mortality and graft loss risk after liver transplantation (LT) in patients with recurrent primary biliary cholangitis (PBC) Aldo Montano-Loza Received Received
  THU-453 Associations between novel serum biomarkers chitinase-2-like protein (YKL-40), type IV collagen, and thrombospondin-2 (TSP-2) with fibrosis stage and clinical outcomes in patients with primary sclerosing cholangitis (PSC) Jun Xu Received Received
  SAT-453 Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection on stable nucleos(t)ide analogue therapy: interim results from the randomised phase 2b B-Clear study Man-Fung Yuen Received Received
  THU-454 MRCPTM - derived biliary metrics are associated with disease severity and clinical outcomes in patients with primary sclerosing cholangitis Nora Cazzagon Received Received
  FRI-454 Association of bile acids composition and synthetic pathway with therapeutic effect of bezafibrate in chronic cholestatic liver disease Manami Iida Received Received
  THU-455 Safety and efficacy of the farnesoid X receptor (FXR) agonist cilofexor in a proof-of-concept study in patients with compensated cirrhosis due to primary sclerosing cholangitis (PSC) Jun Xu Received Received
  FRI-455 Reduced hepatic expression of PPAR alpha in primary biliary cirrhosis is modulated by miR-155 Monika Adamowicz Received Received
  FRI-456 cholangiocytes-specific deletion of sphingosine-1-phospholipid receptor 1 attenuate cholestasis induced liver injury and fibrosis zihang yuan Received Received
  THU-456 Association between patient-reported outcome measures and surrogate markers of liver fibrosis in large-duct primary sclerosing cholangitis Emmanuel Selvaraj Received Received
  THU-457 Association between patient-reported outcome measures and severity of cholangiopathy in large-duct primary sclerosing cholangitis Emmanuel Selvaraj Received Received
  FRI-457 Pruriceptor activating compounds in the eneterohepatic cycle in cholestatic itch Frank Wolters Received Received
  FRI-458 Characterising the early inflammatory landscape of primary sclerosing cholangitis Calli Dendrou Received Received
  THU-458 Ultrasound for the diagnosis of gallbladder polyps in PSC: polyps greater than 8 mm indicate malignancy Johannes Altenmller Received Received
  THU-459 Temporal changes in patient-reported outcome measures stratified by liver fibrosis severity in large-duct primary sclerosing cholangitis Emmanuel Selvaraj Received Received
  THU-460 Temporal increase in interquartile range iron-corrected T1 in high-risk patients with large-duct primary sclerosing cholangitis Emmanuel Selvaraj Received Received
  FRI-460 Copper accumulation in chronic cholestatic disease augments liver damage by impairment of mitochondrial function Dennis Koob Received Received
  THU-461 Seladelpar treatment of patients with primary biliary cholangitis (PBC) for 2 years improves the GLOBE PBC score and predicts improved transplant-free survival Yun-Jung Choi Received Received
  FRI-461 The IgG4-related cholangitis autoantigen laminin 511-E8 stabilizes the biliary bicarbonate umbrella in human cholangiocytes David Trampert Received Received
  THU-462 Validation of a novel method of identifying patients with Primary Sclerosing Cholangitis (PSC) in a canadian population Harshil Patel Received Received
  FRI-462 The risk-variant rs56258221 at the BACH2-locus associates with skewed polarization of naive CD4 T cells towards pro-inflammatory phenotypes in primary sclerosing cholangitis Jonas Bahn Received Received
  FRI-463 Single-cell profiling of liver B cells identifies distinct gene expression and reactivities of expanded B cell clonotypes in primary sclerosing cholangitis Brian K. Chung Received Received
  THU-463 The prevalence of primary biliary cholangitis (PBC) is on the rise: a canadian population-based study Bryce Tkachuk Received Received
  FRI-464 The rs429358 apolipoprotein E (APOE) polymorphism is associated with increased liver injury in patients with autoimmune hepatitis Maciej K. Janik Received Received
  THU-464 Rituximab is a safe and effective treatment for patients with autoimmune hepatitis: results from the Spanish registry for cholestatic and autoimmune hepatitis Mar Riveiro-Barciela Received Received
  FRI-465 Intrabiliary injection of MAIT antigens induces cholangitis in mice Kathrine Sivertsen Nordhus Received Received
  THU-465 Autoimmune hepatitis diagnosed after COVID-19 vaccination. Results from the spanish registry for autoimmune and cholestatic hepatitis Ana Barreira Received Received
  THU-466 A prospective trial of a gluten free diet in primary sclerosing cholangitis with associated colitis Timur Liwinski Received Received
  FRI-466 TGF beta 2 fuels inflammation and fibrosis in cholestatic liver disease through macrophage and myofibroblast recruitment and activation Jan Albin Received Received
  THU-467 The international autoimmune hepatitis group retrospective registry: quality assessment and analysis of clinical characteristics and liver-related outcome Charlotte Slooter Received Received
  FRI-467 Liver-specific Tsg101 depletion causes apoptosis, cell death and liver failure Surui Wang Received Received
  THU-468 Liver inflammation activity in autoimmune hepatitis patients with normal ALT and IgG levels Jiacheng Liu Received Received
  FRI-468 B cell reactivation in autoimmune hepatitis after immunosuppression withdrawal Elena Perpiñan Received Received
  FRI-469 Serum sterols indicate modified cholesterol homeostasis in cirrhotic patients with PBC and correlate with response to treatment with ursodeoxycholic acid Wiktor Smyk Received Received
  THU-469 Novel screening test for primary sclerosing cholangitis: the role of serology, liver function tests, histology and radiology Nina Barner-Rasmussen Received Received
  FRI-470 Preserved MAIT cell proinflammatory function in children with Autoimmune Liver Disease Suz Warner Received Received
  THU-470 More than just an itch: impact of cholestatic pruritus in primary biliary cholangitis (PBC) on health-related quality of life (HRQoL) Helen Smith Received Received
  THU-471 Isolated IgG elevation is not associated with worse outcome in patients with autoimmune hepatitis ALVARO DIAZ GONZALEZ Received Received
  THU-472 Linerixibat doseresponse analysis of C4 concentrations as a quantitative approach to predict gastrointestinal tolerability Fernando Carreño Received Received
  THU-473 Urinary sulfated progesterone metabolites are diagnostic markers for cholestatic pregnancy and markers of treatment response to ursodeoxycholic acid Luiza Borges Manna Received Received
  THU-474 COVID-19 vaccine induced autoimmune hepatitis - a first case series from India Sowmya Iyengar Received Received
  THU-475 Lymphoma in IgG4-related disease: should we be concerned? Arif Hussenbux Received Received
  THU-476 Measurement properties of the PBC-10 in a dutch population Maria van Hooff Received Received
  THU-477 Gluco-regulatory disturbances in primary biliary cholangitis and non-alcoholic fatty liver disease compared with healthy individuals Anne-Sofie Houlberg Jensen Received Received
  THU-478 Proportion of time and degree to which liver biochemistries are out-of-range predicts time to first occurrence of negative hepatic outcomes in people with primary biliary cholangitis TImothy Ritter Received Received
  THU-479 Outcomes following immune checkpoint inhibitor re-challenge in patients who developed grade 3 and 4 hepatotoxicity Amy Hicks Received Received
  THU-480 Development of a novel MRCP-score for patients with primary sclerosing cholangitis, and assessment of agreement and prognostic value ARISTEIDIS GRIGORIADIS Received Received
  THU-481 Right and left lobe biopsies by mini-laparoscopy reveals clinically significant sampling error in staging and grading in AIH johannes hartl Received Received
  THU-482 Should we seek complete liver tests normalization in primary biliary cholangitis? Data from ColHai Registry Maria Carlota Londoño Received Received
  THU-483 Home-based Exercise in patients with refractory fatigue associated Primary Biliary Cholangitis: Final results from the EXerCise Intervention in cholesTatic LivEr Disease (EXCITED) clinical trial Alice Freer Received Received
  THU-484 Long-term obeticholic acid (OCA) for primary biliary cholangitis (PBC) in a clinical trial improved event free survival (death, liver transplant and hepatic decompensation) compared to external controls from the GLOBAL PBC real-world database Joe Konen Received Received
  FRI-485 TIPS insertion leads to partial reversal of systemic inflammation in patients with decompensated liver cirrhosis Lena Stockhoff Received Received
  THU-485 Investigation of linerixibat 40mg BID for cholestatic pruritus of primary biliary cholangitis (PBC); further data from the Phase 2b GLIMMER study to support the Phase 3 GLISTEN study James Fettiplace Received Received
  SAT-486 Evaluation of Interleukin-6 for stepwise diagnosis of minimal hepatic encephalopathy in patients with liver cirrhosis Simon Johannes Gairing Received Received
  THU-487 Post-COVID-19 CHOLANGIOPATHY: Does SARS-CoV-2 play a relevant role in HISTOPATHOLOGICAL findings? Valéria Ferreira de Almeida e Borges Received Received
  FRI-487 Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW) Alessandra Mangia Received Received
  SAT-487 Evaluation of statins as a new therapy to alleviate chronotropic dysfunction in cirrhotic rats Qamar Niaz Received Received
  THU-488 Examining the role of thiopurine metabolite testing in the management of patients with autoimmune hepatitis Andrew Roberts Received Received
  FRI-488 A simple model for predicting survival in cirrhotic patients undergoing portosystemic shunt embolization Won-Mook Choi Received Received
  SAT-488 The effect of sarcopenia on survival of patients with cirrhosis: a systematic review and meta-analysis Xinxing Tantai Received Received
  THU-489 Patient reported symptom burden in primary biliary cholangitis and how to inform trial design Aaron Wetten Received Received
  FRI-489 Blunted cardiovascular effects of beta-blockers in patients with cirrhosis: relation to severity? Puria Nabilou Received Received
  SAT-489 Effectiveness of probiotics in the secondary prevention of hepatic encephalopathy among cirrhotic patients Muhammad Farooq Hanif Received Received
  THU-490 A randomized control trial evaluating the impact of a web-based mind-body wellness intervention for patients with primary biliary cholangitis Makayla Watt Received Received
  SAT-490 Sarcopenia as a predictor of mortality and complications in cirrhosis patients - A prospective cohort study NIDHIN DEVADAS Received Received
  FRI-490 Gender affects the association between serum creatinine levels and clinical response to terlipressin in patients with hepatorenal syndrome type of acute kidney injury Khurram Jamil Received Received
  FRI-491 A novel cirrhotic ascites severity score predicts one-year mortality better than the classification into refractory or diuretic-responsive ascites Rasmus Hvidbjerg Gantzel Received Received
  SAT-491 Diagnosis and pathophysiological analysis of sarcopenia using liver MR in chronic liver disease ATSUSHI NAKAMURA Received Received
  THU-491 Health-related quality of life in patients with primary sclerosing cholangitis: a longitudinal population-based cohort study Bregje Mol Received Received
  FRI-492 A network meta-analysis of numbers needed to treat to prevent an episode of overt hepatic encephalopathy in patients with cirrhosis treated for at least 6 months with lactulose alone, or lactulose plus rifaximin-alpha Eric Ngonga Kemadjou Received Received
  SAT-492 Use of a cirrhosis database can positively impact patient care in United Kingdom practice Jessica Shearer Received Received
  THU-493 COVID-19 in patients with cirrhosis: insights from the multinational LEOSS registry Jonathan Frederik Brozat Received Received
  SAT-493 Psychomotor speed from minimal hepatic encephalopathy testing is associated with physical frailty in patients with end-stage liver disease Alexandra Steinberg Received Received
  FRI-493 Transjugular intrahepatic portosystemic shunt versus balloon-occluded transvenous obliteration for the management of ectopic varices Ranya Selim Received Received
  FRI-494 Identification of potential new serum biomarkers for clinically significant portal hypertension by proteomic profiling of circulating extracellular vesicles Frane Pastrovic Received Received
  SAT-494 A multistrain probiotic increases serum glutamine/glutamate ratio in patients with cirrhosis. A metabolomic analysis German Soriano Received Received
  THU-494 Serum metabolites on admission associate with the development of nosocomial infections in inpatients with cirrhosis Jasmohan S Bajaj Received Received
  THU-495 Association of impaired neutrophil migration with adverse outcomes in patients with liver cirrhosis Mona-May Langer Received Received
  FRI-495 Factors influencing survival in cirrhotic patients with hepatic hydrothorax Sarah Romero Received Received
  SAT-495 The composition of the bile acid pool is closely associated with fibrosis in the heart and liver of patients with cirrhosis Signe Wiese Received Received
  FRI-496 Hepatic venous pressure gradient (HVPG) measured at events is lower in non-alcoholic fatty liver disease (NAFLD) associated cirrhosis as compared to alcoholic cirrhosis Svetlana Adamcova Selcanova Received Received
  THU-496 Renal and circulatory effects of terlipressin in patients with hepatorenal syndrome assessed by magnetic resonance imaging Puria Nabilou Received Received
  SAT-496 SBP vs. non-SBP bacterial infections at admission have comparable outcomes in a multi-center cohort of inpatients with cirrhosis Jacqueline OLeary Received Received
  FRI-497 Low subcutaneous adipose tissue is associated with mortality independently from portal hypertension in patients with cirrhosis Amine Benmassaoud Received Received
  THU-497 SARS-CoV-2 infection in patients with underlying chronic liver disease is associated with significantly greater risks of inpatient hospitalization, intensive care unit admission, and overall mortality Robert Wong Received Received
  SAT-497 Natural history of Hepatic Encephalopathy (HE) in a tertiary referral centre for hepatology Chiara Mangini Received Received
  FRI-498 Association of low mechano-energitic efficiency and prognosis in liver cirrhosis Sren Mller Received Received
  THU-498 Low FT3 levels are associated with acute decompensation and acute-on-chronic liver failure Mona-May Langer Received Received
  SAT-498 Public knowledge and attitudes toward liver diseases and liver cancer in the brazilian population Paulo Bittencourt Received Received
  THU-499 Post hoc analyses of the ATTIRE trial suggest potential gender differences in response to albumin Alastair OBrien Received Received
  SAT-499 The negative impact of the pandemic on hospital admissions, morbidity and 30-day mortality for acute cirrhosis decompensation: a tertiary care perspective Kohilan Gananandan Received Received
  FRI-499 Long term albumin administration is associated with reduced healthcare resource use in patients with uncomplicated cirrhotic ascites: results from a simulation model Elisabet Viayna Received Received
  SAT-500 Comparison of recommended daily energy intakes in people with cirrhosis, based on current guidelines, and their directly measured energy requirements: an individual patient data analysis Marsha Morgan Received Received
  FRI-500 Improved survival rates in hepatic encephalopathy after a decade of clinical practice with the addition of rifaximin-alpha to lactulose: a real-world data meta-analysis Juha Halonen Received Received
  THU-500 Can machines predict liver decompensation? Analysis of 1,415 patients with liver cirrhosis recruited at three German referral centers Sophie Elisabeth Mller Received Received
  SAT-501 Rifaximin for the prevention and treatment of hepatic encephalopathy: a systematic review and meta-analysis of randomized clinical trials Marsha Morgan Received Received
  FRI-501 Risk prediction of hepatic encephalopathy after molecular targeted therapy for hepatocellular carcinoma in patients with cirrhosis Kisako Fujiwara Received Received
  THU-501 LivR Well: a feasibility study for a home-based, multidisciplinary liver optimization program for the first 28 days after an admission for acute-on-chronic liver failure Natalie Ngu Received Received
  SAT-502 Infuence of cirrhotic cardiomyopathy defined according to the new multidisciplinary diagnostic criteria on overall mortality among cirrhotic patients Simona Bota Received Received
  FRI-502 ABC: a novel algorithm to stratify decompensation risk in patients with cACLD (CHESS2102): an international, multicenter cohort study Chuan Liu Received Received
  THU-502 Alcohol-associated hepatitis with acute-on-chronic liver failure in a diverse cohort: lung and circulatory organ failures along with MELD 35 are predictive of mortality Stephanie Rutledge Received Received
  THU-503 Bilirubin and its dynamics are independently associated with mortality in patients with acute decompensation of cirrhosis Konstantin Kazankov Received Received
  FRI-503 Quantitative parameters of esophageal varices based on computed tomography may be used for predicting severe varices in patients with liver cirrhosis Shang Wan Received Received
  SAT-503 Risk of herpes zoster infection in patients with cirrhosis: a nationwide population-based study in Korea DONGSUB JEON Received Received
  FRI-504 A cost-effectiveness evaluation of the GORE VIATORR TIPS Endoprosthesis versus large volume paracentesis in the management of portal hypertension complications in the Spanish healthcare system Mitesh Nakum Received Received
  THU-504 Impact of predisposition and precipitants on the short-term prognosis among inpatients with chronic liver disease Yan Zhang Received Received
  SAT-504 Skeletal muscle pathological fat infiltration (myosteatosis) associates with higher mortality in patients with cirrhosis Maryam Ebadi Received Received
  FRI-505 Factor VIII/protein C ratio does not reflect coagulation but is linked to pathophysiological mechanisms driving disease progression in patients with advanced chronic liver disease Lorenz Balcar Received Received
  THU-505 A study evaluating outcomes of a virtual specialist liver cirrhosis clinic Claudia Moore-Gillon Received Received
  SAT-505 Application of CT-contrast media is not associated with a higher risk for acute kidney injury in patients with decompensated liver cirrhosis Tammo Lambert Tergast Received Received
  SAT-506 Proton pump inhibitors are associated with higher mortality risk and higher risk of decompensation in patients with liver cirrhosis - A retrospective cohort study from the Amsterdam metropolitan area Koos de Wit Received Received
  FRI-506 Prognostic impact of variants in TM6SF2 and MBOAT7 in patients who have progressed to advanced chronic liver disease Lorenz Balcar Received Received
  THU-506 A novel metabolomics-based prognostic model shows superior diagnostic accuracy than MELD in chronic liver failure Rudolf E. Stauber Received Received
  THU-507 Uncovering monocyte transcription, functional and metabolic signatures in recovery and non-recovery ACLF patients Rita Furtado Feio de Azevedo Received Received
  FRI-507 Hepatocellular carcinoma and number of elastic bands per session are strong predictors of bleeding after prophylactic endoscopic variceal bleeding Renato Medas Received Received
  SAT-507 Maintenance of sarcopenia and myosteatosis after liver transplantation Franziska Recklies Received Received
  SAT-508 Clinical and prognostic characterization of the patterns of decompensation of liver cirrhosis Marta Tonon Received Received
  THU-508 Early initiation of continuous renal replacement therapy improves renal outcomes and survival in patients with acute on chronic liver failure - a prospective cohort study Rakhi Maiwall Received Received
  FRI-508 Simultaneous large spontaneous portosystemic shunt embolization for the prevention of overt hepatic encephalopathy after TIPS: a randomized controlled trial Guohong Han Received Received
  THU-509 Different clinical courses of acutely decompensated cirrhosis in hepatitis B virus high-endemic area: data from Chinese Acute-on-Chronic Liver Failure (CATCH-LIFE) study Tongyu Wang Received Received
  FRI-509 Use of second-harmonic generation microscopy for automated detection of septa and nodules in needle liver biopsies of NASH cirrhosis Mazen Noureddin Received Received
  THU-510 Characterization of energy and substrate metabolism in patients with spontaneously breathing and mechanically ventilated patients with liver cirrhosis: an indirect calorimeter based study Varsha Shasthry Received Received
  FRI-510 Hepcidin is higher in patients with more severe liver disease independent of portal hypertension Robin Greinert Received Received
  SAT-510 Serological assessment of the collagen type III deposition predicts outcome in decompensated liver cirrhosis Mette Juul Nielsen Received Received
  THU-511 Extracorporeal membrane oxygenation, a valuable life-saving treatment in liver transplanted patients Benjamin Buchard Received Received
  SAT-511 Liver frailty index predicts poor outcomes in patients hospitalized for acute decompensation of cirrhosis Simone Incicco Received Received
  FRI-511 Effect of thrombocytopenia and platelet transfusion on outcomes of acute variceal bleeding: a real world experience Sagnik Biswas Received Received
  THU-512 Prevalence, profile and predictors of invasive fungal infections in acute on chronic liver failure (ACLF): analysis of APASL-ACLF research consortium database Pratibha Ramchandra Kale Received Received
  SAT-512 Urinary proteomics identifies oxidative stress and inflammation pathways as key factors differentiating acute-kidney injury-hepatorenal syndrome from acute tubular necrosis in patients with cirrhosis Laura Napoleone Received Received
  FRI-512 Personalized preemptive TIPS treatment for patients with Child-Pugh B cirrhosis and acute variceal bleeding by applying individualized of prediction of treatment effect Guohong Han Received Received
  THU-513 Outcomes in patients with cirrhosis and fungal infections: a systematic review and meta-analysis with machine learning Nipun Verma Received Received
  SAT-513 Kidney transplant alone recipients with advanced liver disease have similar outcomes to those without advanced liver disease - a single center study of 150 patients Rohit Nathani Received Received
  FRI-513 Real-world survival outcomes in patients with decompensated cirrhosis receiving long term human albumin infusions Nicholas Hannah Received Received
  SAT-514 Clinical features of exacerbation of portal vein thrombosis after discontinuation of anticoagulants Takayuki Kondo Received Received
  THU-514 Impact of de presence of acute on chronic liver failure on morbi - mortality after liver transplantation Jorge Arnold Received Received
  FRI-514 Impact of non-ive beta-blockers on survival and liver-related complications after TIPS-Insertion Anja Tiede Received Received
  SAT-515 Systemic inflammatory response syndrome and renal resistive index as early predictors of treatment response to terlipressin in hepatorenal syndrome-acute kidney injury Vijay Narayanan Received Received
  FRI-516 Derivation of machine learning histologic scores correlating with portal pressures and the development of varices in NASH patients with cirrhosis Mazen Noureddin Received Received
  THU-516 Untargeted lipidomics differentiate ACLF precipitated by severe alcoholic hepatitis florent Artru Received Received
  THU-517 Metabolomic analysis of organ failure marker compounds in blood samples of patients with decompensated liver cirrhosis after administration of the novel drug VS-01 wenyi gu Received Received
  SAT-517 Identification of overt hepatic encephalopathy precipitating factors: a pooled analysis of 3 clinical trials of rifaximin plus lactulose Jasmohan S Bajaj Received Received
  FRI-517 Ruling out varices needing treatment with a non-invasive score in patients with compensated HBV cirrhosis Giacomo Emanuele Maria Rizzo Received Received
  SAT-518 Dementia frequently co-exists with hepatic encephalopathy but not other cirrhosis complications in US veterans with cirrhosis Adeyinka Adejumo Received Received
  THU-518 Metabolomic analysis of bacterial infection markers in blood samples of patients with decompensated liver cirrhosis infused with the novel drug VS-01 Olaf Tyc Received Received
  FRI-518 Evaluation of clinically significant portal hypertension with a novel spleen-dedicated probe using transient elastography Aitor Odriozola Herrán Received Received
  THU-519 Disturbances in sodium and chloride hemostasis predict outcome in stable and critically-ill patients with cirrhosis - not two sides of the same coin Georg Semmler Received Received
  FRI-519 Are psychometric tests helpful for the prediction of hepatic encephalopathy after TIPS insertion? Alena Friederike Ehrenbauer Received Received
  SAT-519 Bacterial infections as a predisposing factor for the development of portal vein thrombosis in cirrhotic patients: a prospective study Leonardo De Marco Received Received